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GENERAL INTRODUCTION 
Primary osteoporosis is an age-related disorder characterized by a decrease in bone 
mass, causing susceptibility to bone fractures (1). It affects an estimated 15-20 million 
people in the United States (1), both men and women, although women have a much greater 
risk (1,2). Of women over 65, one-third will suffer vertebral fractures (2). Some risk 
factors that can lead to development of osteoporosis include genetic background (3,4,5), 
aging (2), female gender (1,2), estrogen or testosterone deficiency (1,6,7), poor nutrition 
(1, 2), low peak bone density (1, 8), lack of exercise (2), and disease (2). 
The active hormonal form of vitamin D3, 1,25-dihydroxyvitamin D3 [l,25(OH)2D3] 
plays a major role in maintenance of bone mineral homeostasis (9). Intracellular 
1,25(0H)2D3 receptors (VDR) mediate the effects of l,25(OH)2D3 in the major target 
tissues of kidney, bone, and intestine (9). Changes in l,25(OH)2D3 metabolism or VDR 
expression may affect target tissue responsiveness. The l,25(OH)2D3 up-regulates its 
receptor in vitro (10,11). Vitamin D-dependent calcium (Ca) binding proteins (CaBP-28K 
and CaBP-9K), which seem to be involved in regulation of Ca absorption, also are 
regulated by l,25(OH)2D3 through its receptor (12, 13). The 25-hydroxyvitamin D3 
[25(0H)D3] is converted to l,25(OH)2D3 in the kidney by the 25-hydroxyvitamin D-la-
hydroxylase enzyme (1 «-hydroxylase) (14, 15). Inactive metabolites [24,25(OH)2D3, 
1,24,25(011)303] are produced by the la,25-dihydroxyvitamin D-24-hydroxylase (24-
hydroxylase) in target tissues such as kidney and intestine (14, 15). In the kidney, 
parathyroid hormone (PTH) induces the activity of la-hydroxylase and suppresses 24-
hydroxylase activity (16, 17). The l,25(OH)2D3 induces 24-hydroxylase activity in both 
kidney and intestine (18, 19, 20, 21). Parathyroid hormone does not down-regulate 24-
hydroxylase activity in intestine (22). Additionally, sex steroids may play a role in 
regulation of Ca balance, because of their direct effects on bone cells in vitro (23,24). 
With aging, plasma PTH concentrations tend to be chronically elevated (25, 26), 
production of l,25(OH)2D3 decreases (27,28), and intestinal Ca absorption becomes less 
efficient (29, 30). Concentrations of sex steroids, particularly estrogen after the menopause 
in females, also decrease with aging (6,7). 
The purpose of the experiments described in this dissertation was to examine more 
in depth the regulation of factors involved in maintenance of bone mineral homeostasis at the 
cellular and molecular level. Specifically, gene products whose expression are regulated by 
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1,25(0H)2D3 were examined, including VDR, CaBP-9K, CaBP-28K, and 24-hydroxylase 
in both kidney and duodenum. Differences in regulation of these proteins was examined in 
male and female rats, both young and old, in response to dietary Ca deficiency and 
supplementation, and dosing with l,25(OH)2D3. 
It is hoped that further knowledge gained by these studies will provide a better 
understanding of the processes involved in development of osteoporosis, and so lead to 
improved treatment and prevention. 
Explanation of Dissertation Format 
This dissertation consists of two separate manuscripts. Each paper is complete in 
itself, with an abstract, introduction, materials and methods, results, discussion, and 
references. A literature review for the dissertation is included before the first manuscript, 
and a general discussion of the combined results is included after the third manuscript. An 
appendix containing additional information pertinent to the manuscripts is included at the 
end of the dissertation. References cited in the general introduction, literature review, 
general discussion, and appendix are listed following the general discussion. 
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LITERATURE REVIEW 
The purpose of this review is to summarize current knowledge regarding the effects 
of aging and gender differences on factors involved in the regulation of bone mineral 
homeostasis, and how these factors are involved in the development of involutional 
osteoporosis. Better understanding of the mechanisms by which these factors regulate bone 
mineral homeostasis can lead to more effective measures for prevention and treatment of 
osteoporosis. 
Osteoporosis 
Osteoporosis is a bone disorder characterized by an absolute decrease in the amount 
of bone, leading to heightened susceptibility to fractures (1, 31, 32). Idiopathic 
osteoporosis can occur in juveniles and young adults (31). Osteoporosis also can be caused 
by medical conditions, certain drugs, or surgery, such as ovariectomy, hypogonadism, 
hyperthyroidism, and treatment with glucocorticoids (31). This is termed secondary 
osteoporosis. Osteoporosis generally, however, is considered a disease of aging (i.e., 
involutional osteoporosis). Hip fractures have been recognized as a result of osteoporosis 
in the elderly for over a century (33), and vertebral fractures have been associated with 
postmenopausal osteoporosis for more than 50 yr (34). In the United States alone, an 
estimated 1.5 million fractures occur every year as a result of osteoporosis, leading to an 
estimated cost to society of $7-$ 10 billion annually. This cost is mostiy related to hip 
fracture, which is fatal in 12-20% of cases, with 25% of survivors confined to long-term 
nursing home care (31, 35). 
Bone mass in humans increases during development and growth until around age 
30, followed by a short period of stability, after which age-related bone loss begins (31, 36, 
37). Over the life span, women can expect to lose about 35% of their cortical bone and 50% 
of trabecular bone, and men can expect to lose about 23% and 33%, respectively (31, 38). 
Bone is a dynamic tissue, constantiy turning over. This remodeling takes place within bone 
remodeling units (BRU). In a normal cycle of bone remodeling, osteoclasts resorb bone, 
creating lacunae in the bone (37, 39). Osteoclasts attach tightly to the bone surface, forming 
a sealed compartment into which lysosomal enzymes and protons are secreted (39). 
Osteoclast attachment to bone is mediated by integrins, which are cell surface adhesion 
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molecule receptors (39). This resorption process occurs over a period of about 2 wk. 
Osteoblasts then replace the osteoclasts, filling in the resorptive cavities, over a 3-4 mo 
period, to create a new structural unit of bone (37). During bone loss, resorption and 
formation are uncoupled, with a relative increase in resorption over formation (3, 31). 
Trabecular bone is found primarily in the vertebrae, pelvis, flat bones, and the ends of long 
bones. Cortical bone predominates in the shafts of long bones. With its greater surface 
area, trabecular bone is much more metabolically active than cortical bone, and so is more 
responsive to changes in mineral homeostasis (3). 
Bone loss occurs biphasically. First, there is a slow rate of bone loss over the 
lifetime, after achievement of peak bone density (3). This slow phase occurs in both men 
and women, and is age-dependent. The slow phase starts around age 40 in cortical bone, 
and possibly as early as age 30-35 in trabecular bone. Bone loss in the slow phase results 
primarily from impaired osteoblast activity (3). That is, the osteoblasts fail to completely fill 
the resorptive cavities made by osteoclasts in the cycle of bone remodeling. 
The second type of bone loss is an accelerated phase of bone loss that occurs in 
women after the menopause (31). Bone loss in the accelerated phase is due mostly to high 
turnover rate, when a greater number of osteoclasts are active and create deeper lacunae (3, 
31). Bone formation also may increase, but the increase in rate of resorption is even 
greater. The accelerated phase occurs immediately following the menopause in both cortical 
and trabecular bone. The rapid rate of bone loss decreases to slow phase rates after 8-10 yr 
in cortical bone. In trabecular bone, however, there may be a greater initial rate of 
accelerated bone loss compared with cortical bone, but the duration of accelerated bone loss 
is shorter. A major portion of trabecular bone loss occurs even before the onset of 
menopause, and cortical bone loss occurs mostly post-menopausally (7, 31,40). 
Osteoblasts in osteoporotic patients seem to respond normally to proliferative stimuli 
(31, 37,41). It therefore seems that changes that occur during aging are in the stimulating 
factors. For example, growth hormone and insulin-like growth factor-I have been shown to 
decrease with age (42,43). Many other factors involved in maintenance of bone mineral 
content undergo changes with aging. These will be discussed in later in this review. 
Several steps can be taken to prevent bone loss that occurs with aging and/or 
menopause. Estrogen replacement therapy, along with dietary Ca supplementation, is the 
most effective treatment currentiy available for slowing bone loss following menopause (31, 
32, 44). Menopause, however, is only one of several causal factors; vertebral bone loss 
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begins well before menopause (7, 31,40). Estrogen and Ca act mainly to decrease the 
activity of new BRU (45,46). Calcium also may act to decrease PTH secretion (44,47). 
Because bone cells contain estrogen receptors (23, 48), it is likely that estrogen also acts 
directly on bone cells to counteract the stimulation of resorptive activity by PTH. An 
alternative treatment to estrogen replacement is calcitonin (CT), which may act directly on 
osteoclasts to decrease resorption (31,49). Several different bisphosphonates also are 
being tested (31, 50,51). These compounds are taken up by the skeleton, actually 
increasing bone mass, and possibly inhibiting resorption through toxicity to osteoclasts, or 
by making bone more resistant to digestion by osteoclasts. More recently, echistatin, an 
integrin antagonist, has been shown to prevent osteoclast attachment to bone surface and to 
completely inhibit osteoclast-mediated bone resorption in vivo (52). Regular weight-bearing 
exercise stimulates osteoblast function, and increases bone density (53, 54). Muscle mass 
and bone mass, in fact, are directly related (55). 
Despite the great benefits of estrogen replacement therapy in treatment of 
postmenopausal osteoporosis, estrogen deficiency does not entirely explain the accelerated 
bone loss associated with menopause. Serum concentrations of sex steroids are similar in 
postmenopausal women both with and without osteoporosis (31, 32, 56). Some 
postmenopausal osteoporotic patients do not respond to currently available therapies (57). It 
is hypothesized that these patients may have intrinsic abnormalities in osteoblast function, 
preventing stimulation of bone formation much above basal levels (31, 57). These 
observations, along with the fact that slow phase bone loss begins even before menopause 
(7,40), suggest that other factors involved in regulating bone mineral metabolism also must 
play a part in determining individual susceptibility to involutional osteoporosis. 
Factors Involved in Regulation of Bone Mineral Homeostasis 
The PTH-vitamin D endocrine system is the major regulator of Ca balance (58). 
Concentrations of Ca in extracellular fluid (ECF) and plasma are maintained within a 
relatively narrow range, and deviations from this range can have serious consequences (58, 
59). When deviations do occur, this system acts to normalize plasma Ca concentrations 
through multiple mechanisms. 
In a state of normal Ca balance, net intestinal Ca absorption and renal Ca excretion 
are approximately equal (59). An average adult human ingests around 15 mg/kg body 
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weight of Ca daily. Of this, about 11 mg/kg is excreted in the feces, and 4 mg/kg enters the 
ECF and plasma Ca pool. This extracellular Ca pool equilibrates with bone Ca pools, and, 
to a lesser extent, with intracellular Ca pools. Upon filtration through the kidney, about 4 
mg/kg of Ca is excreted in urine (59). 
In response to decreased plasma Ca concentrations, greater amounts of PTH are 
secreted (44,47). This PTH acts to decrease renal Ca excretion, increase mobilization of Ca 
from bone, stimulate renal production of 1,25-dihydroxyvitamin D3 [l,25(OH)2D3] (47), 
and suppress 24-hydroxylase catabolism of l,25(OH)2D3 (9, 22, 60,61). Resulting 
1,25(0H)2D3 increases CaBP-9K and CaBP-28K expression (58). This may increase 
intestinal Ca absorption and decrease kidney Ca excretion (58,62,63). The l,25(OH)2D3 
also acts directly on bone cells to stimulate Ca mobilization (64, 65). The l,25(OH)2D3 
receptors (VDR) have been found in osteoblasts but are not present in osteoclasts (66). 
In the case of excessive plasma Ca concentrations, PTH release is suppressed, and 
release of CT is stimulated (44,47,59). The CT acts to increase renal excretion of Ca, 
decrease mobilization of bone Ca, and stimulate renal l,25(OH)2D3 synthesis (59, 66, 67). 
The subsequent drop in plasma l,25(OH)2D3 concentration leads to suppression of PTH 
secretion (68), a decrease in mobilization from bone and decreased absorption of Ca in tiie 
intestine (64, 66). 
Vitamin D 
Vitamin D has been found to have many roles in addition to its classical role in 
regulation of mineral homeostasis. In addition to the classical target tissues of bone, 
intestine, and kidney (64), more recent research has shown l,25(OH)2D3 to have activity in 
many other tissues, including, but not limited to, skeletal and smooth muscles (69, 70, 71), 
brain, and pituitary gland (72), pancreas (73, 74), liver (69,75), and hematopoietic and 
immune system cells (76, 77, 78, 79). The l,25(OH)2D3 enhances cardiac and vascular 
muscle contractile function, modulates blood pressure, and inhibits excessive expression of 
myocardial collagen (70). In skeletal muscle, l,25(OH)2D3 affects cell division and 
differentiation, alters phospholipid metabolism, and induces specific proteins (71, 80). The 
1,25(0H)2D3 affects hormone production and secretion in the pituitary, playing a 
permissive role in enhancing agonist-induced production of prolactin releasing hormone and 
thyrotropin-stimulating hormone (72). In the pancreas, l,25(OH)2D3 stimulates insulin 
secretion by a direct effect on the (3-cells (73,74). The l,25(OH)2D3 restores the ability of 
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hepatocytes to induce DNA polymerase-a activity and initiate DNA synthesis after partial 
hepatectomy (75). The l,25(OH)2D3 regulates growth and differentiation of several cell 
types in the hematopoietic and immune systems (76). It enhances immune responses in 
some cases (77, 78) and suppresses them in others (79). This brief description is not 
intended to cover all that is currentiy known about the numerous actions of vitamin D. The 
focus of this review will be on the role of vitamin D in regulation of bone mineral 
homeostasis. 
Vitamin D metabolism 
Vitamin D is not truly a vitamin but currently is classified as a steroid hormone (9, 
60, 64, 81). Vitamin D is a seco-steroid, which is ingested in the diet or can be synthesized 
in the skin from 7-dehydrocholesterol upon exposure to UV irradiation (9, 60, 64). 
Recognition that sunlight exposure could produce adequate amounts of vitamin D eliminated 
rickets as a major health problem (1). Vitamin D metabolites are carried in the bloodstream 
by the vitamin D binding protein (DBF) (9, 64, 82). In the liver, vitamin D is converted to 
the inactive metabolite 25(OH)D3 by 25-hydroxylase, a cytochrome P450-containing 
enzyme (9, 60, 64). 
Subsequently, 25(OH)D3 is hydroxylated again in the kidney by the la-hydroxylase 
enzyme complex, which is made up of a flavoprotein, ferredoxin, and a cytochrome P450 
(60) and is located mainly in mitochondria of the proximal renal tubules (60, 83, 84). This 
reaction produces l,25(OH)2D3, the metabolically active hormonal form of vitamin D. The 
la-hydroxylation is the rate-limiting reaction in l,25(OH)2D3 synthesis (1, 83). The 
activity of la-hydroxylase is regulated by several factors. Low plasma Ca concentrations 
stimulate PTH secretion (60, 83), possibly through a mechanism mediated by a Ca-
activated, phospholipid-dependent protein kinase (PKC) (85). Parathyroid hormone 
stimulates the la-hydroxylase enzyme by increasing the intracellular messenger cyclic 
adenosine monophosphate (cAMP) (86, 87). Activation of la-hydroxylase by PTH also is 
associated with dephosphorylation of the renal ferredoxin (83, 88, 89). Phosphorous (P) 
deficiency increases la-hydroxylase activity (90, 91, 92). Through a feedback mechanism, 
high plasma concentrations of l,25(OH)2D3 inhibit la-hydroxylase activity (60, 87, 92), 
and 1,25(0H)2D3 deficiency stimulates la-hydroxylase activity (93). 
Both 25(0H)D3 and 1,25(0H)2D3 can be hydroxylated by kidney 24-hydroxylase 
to form 24,25(0H)2D3 and 1,24,25(0H)3D3, respectively (1,9, 60). It is debated whether 
or not 24,25(0H)2D3 has any biological activity, but synthesis of l,24,25(OH)3D3 is 
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considered the first step in a catabolic inactivation pathway (9, 64). The kidney 24-
hydroxylase is also cytochrome P450-dependent and is regulated reciprocally with la-
hydroxylase (9, 60, 64, 87, 94). That is, adequate plasma Ca or elevated plasma PTH 
concentrations suppress kidney 24-hydroxylase activity (9, 22, 60, 61, 64), and high 
concentrations of plasma l,25(OH)2D3 stimulate activity by increasing activity of the 
enzyme (60, 61, 87). Vitamin D deficiency results in suppression of renal 24-hydroxylase 
activity (93). The 24-hydroxylase is also found in several other tissues, including the major 
target tissue of the intestine, where it is regulated differently from the kidney enzyme (22). 
Parathyroid hormone does not down-regulate intestinal 24-hydroxylase activity (22), but 
1,25(0H)2D3 does induce the enzyme in intestine as in kidney (22,90). Dietary Ca 
restriction leads to up-regulation of intestinal 24-hydroxylase through increased plasma 
1,25(0H)2D3 concentrations. However, despite equivalently increased plasma 
1,25(0H)2D3 concentrations, dietary P restriction did not result in up-regulation of intestinal 
24-hydroxylase (90). Dietary P restriction also does not affect renal 24-hydroxylase activity 
(91, 92). 
Genomic actions of vitamin D 
In the major target tissues of bone, intestine, and kidney, l,25(OH)2D3 exerts its 
biological effects primarily through intracellular VDR (9, 64, 81). The VDR are part of the 
steroid-thyroid receptor gene superfamily of nuclear transcription factors (9,95, 96, 97, 
98). This classification is based on structural similarities with the other receptor proteins, 
including a highly conserved DNA-binding domain (9, 95, 96,97, 98). The VDR exist 
predominantly in the nucleus (9, 97). The receptor protein contains a hormone-binding 
domain near the carboxy-terminus and a DNA-binding domain near the amino-terminus (9, 
95,97). The DNA-binding domain contains two "Zinc (Zn) finger" structures, in which a 
Zn atom is tetrahedrally coordinated through the sulfhydryl moieties of four conserved 
cysteine residues (9,95,97). This DNA-binding domain is highly evolutionarily conserved 
and resembles that seen in other DNA-binding proteins, such as transcription factor IIIA (9, 
95,97). Interaction of l,25(OH)2D3 with VDR results in ligand-dependent 
phosphorylation of certain serine residues (85,99). Ligand-dependent phosphorylation on 
serine residues also is seen with the progesterone receptor (100). 
The interaction of l,25(OH)2D3 with its receptor mediates changes in gene 
transcription of specific proteins. The steroid-receptor complex interacts with a specific 
region of the promoter of a gene, designated as a vitamin D response element (VDRE), and 
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can result in both positive and negative regulation of gene transcription (9, 95, 97). This 
VDRE consists of two direct hexameric repeats, suggesting that VDR may bind as a homo-
or heterodimer (101,102,103). Some evidence implies that VDR does not interact with the 
VDRE as a homodimer (101). Indeed, a 59-64 kDa nuclear activating protein (NAP) is 
essential for VDR binding to VDRE (104, 105). Formation of the NAP-VDR complex is 
independent of l,25(OH)2D3 and DNA, and subsequent interaction with the VDRE does not 
require binding of l,25(OH)2D3, although binding of l,25(OH)2D3 greatly enhances both 
complex formation and DNA binding (104, 105). The retinoid X receptors a and p (RXR-
a and RXR-P) have been identified as possible candidates for this NAP, because they form 
heterodimers with VDR and increase subsequent VDRE binding and transcriptional 
activation (106, 107). Anotiier study, however, gives evidence that the NAP essential for 
VDR interaction with VDRE is not likely to be an RXR (108). Recently, two functionally 
distinct classes of response elements (RE) for vitamin D have been demonstrated (107). In 
the class of REs found in the osteocalcin gene (termed VDRE), transcriptional activation is 
induced by l,25(OH)2D3 alone, probably through binding of VDR homodimers to the 
VDRE. In the class of REs present in the osteopontin gene (termed VD/RXRE), 
1,25(0H)2D3 and 9-c/.y-retinoic acid (the ligand for RXR) act together to induce a 
synergistic response in transcription, through VDR/RXR heterodimers. These RXR-
dependent and RXR-independent mechanisms represent two separate nuclear signalling 
pathways for l,25(OH)2D3, offering more complex control of l,25(OH)2D3-regulated 
genes (107). The disparity in results from the earlier studies that examined RXR-VDR 
interactions may be the result of looking at REs for l,25(OH)2D3 in only one gene, which 
would yield different results depending on the type of RE present in the particular gene 
studied. 
The 1,25(0H)2D3 has been shown to regulate transcription of over 60 genes, 
including CaBP-9K (13, 58), CaBP-28K (13, 58), 24-hydroxylase (22, 60), and 
osteocalcin (9, 109, 110). The l,25(OH)2D3 also up-regulates its own receptor (61, 111). 
Treatment of cells in vitro with l,25(OH)2D3 decreases the binding affinity of VDR for the 
hormone (112). In addition to catabolic degradation pathways, this offers a mechanism for 
controlling the effects of l,25(OH)2D3 on the cell. Ketoconazole, an inhibitor of the 
degradative 24-hydroxylase enzyme, increases homologous up-regulation of VDR, resulting 
in an increased proportion of occupied VDR and prolonged duration of occupation by 
1,25(0H)2D3 (10). 
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Up-regulation of intestinal VDR and CaBP-9K leads to a corresponding increase in 
absorption of dietary Ca (51,58,63,64). When plasma concentrations of l,25(OH)2D3 are 
increased endogenously by dietary Ca deficiency to concentrations similar to those attained 
with exogenous treatment with l,25(OH)2D3, different results are obtained (111). Kidney 
VDR and VDR mRNA are actually down-regulated, and intestinal VDR and VDR mRNA 
are not affected. This most likely is a result of the increase in plasma PTH, which occurs 
during states of Ca deprivation (44,47). Parathyroid hormone negatively regulates 
transcription of VDR both in vitro and in vivo in kidney cells (61). No PTH receptors have 
been found in intestine, however. PTH possibly regulates VDR, and 24-hydroxylase as 
well, through a PKC-mediated cAMP production, resulting in suppression of gene 
transcription (22, 87, 113, 114, 115). 
Non-genomic actions of vitamin D 
More recent studies have implicated another pathway by which l,25(OH)2D3 might 
exert its effects on target tissues. This mode of action involves a signal transduction 
pathway, which is independent of the regulation of gene transcription (81,92). The 
hormone interacts with the cell membrane (possibly through a cell surface receptor), 
resulting in the opening of Ca channels in a response that is too rapid to be a result of gene 
transcription. The main observed biological responses thought to be a result of this rapid 
non-genomic action are transcaltachia (defined as "very rapid stimulation of intestinal Ca 
transport") and the opening of voltage-gated Ca channels in rat osteoblast-like osteosarcoma 
cells (81). This biological response appears within seconds to minutes after treatment with 
1,25(0H)2D3 compared with one or more hours required for genomic responses (81, 92). 
Parathyroid Hormone 
Parathyroid hormone is an 84 amino acid (a.a.) straight chain polypeptide hormone 
synthesized by the parathyroid glands (47). Its secretion is stimulated by a fall in plasma Ca 
concentration and suppressed by above normal Ca concentrations (44,47). The mechanism 
for control of PTH secretion by extracellular Ca concentrations is not clear but seems to 
involve regulation of Ca channels in the plasma membrane (44). The signal generated by 
cell membrane sensors, which sense changes in extracellular Ca concentrations, regulates 
the intracellular Ca concentration, and it is the intracellular Ca pool that interacts to mediate 
PTH secretion (44). This occurs at an intracellular Ca concentration of about 200 nM, 
regardless of the extracellular Ca concentrations (44). The VDR have been found in the 
parathyroid glands and have been shown to bind upstream of the PTH gene (44,116). The 
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1,25(0H)2D3 also suppresses pre-proPTH mRNA expression (44). Both in vitro and in 
vivo studies show that l,25(OH)2D3 inhibits PTH secretion (44, 68). This suppression 
seems to be the result of increased sensitivity of the parathyroid gland to extracellular Ca 
(68). In rat osteoblast-like osteosarcoma cells, glucocorticoid increases and l,25(OH)2D3 
decreases the activation of adenylate cyclase and cAMP-dependent protein kinase (PKA) by 
PTH (117). Parathyroid hormone has reciprocal regulatory effects on VDR, down-
regulating both VDR and VDR mRNA in vitro, and blocking the homologous up-regulation 
of VDR by 1,25(0H)2D3 in vivo (61). It thus seems that PTH and l,25(OH)2D3 have 
opposing effects on certain genes. In a study examining the effects of a 3-wk period of 
dietary Ca and vitamin D deficiency on PTH, Ca deficiency resulted in a 5-fold increase in 
expression of PTH and its mRNA (118). Vitamin D deficiency increased PTH mRNA 
abundance 2-fold (118). Combined Ca and vitamin D deficiency, however, caused a 10-
fold rise in PTH mRNA (118). In control rats, parathyroid gland cells made up 25% of the 
total number of cells from parathyroid-thyroid tissue, whereas parathyroid gland cells made 
up 42% of parathyroid-thyroid tissue in rats deficient in both Ca and vitamin D (118). 
Studies in the bovine parathyroid gland suggest that estrogen and progesterone also 
stimulate PTH secretion (44). 
Parathyroid hormone interacts with high affinity receptors in cells in the renal distal 
tubule to increase Ca reabsorption, urinary excretion of cAMP, and la-hydroxylation of 
25(0H)D3 and to inhibit reabsorption of phosphate and bicarbonate (47). PTH receptors 
also are found on osteoblasts in bone where PTH acts to increase bone resorption (47,59). 
The ability of PTH to stimulate renal cAMP formation upon interaction with its 
receptor resides in the 1-27 a.a. region of the hormone's amino-terminus, which contains 
domains for receptor binding and activation (47). Normal adult plasma contains both intact 
PTH-(l-84) and various fragments of PTH that lack the amino-terminal 1-27 a.a. region 
(47). These fragments are present at a concentration 4- 20-fold greater than that of intact 
PTH. Although the amino-terminal 1-27 a.a. region is considered the bioactive portion of 
PTH, recent studies have reported in vitro biological activity of fragments lacking this 
region, including the 53-84 a.a. region and the 30-34 a.a. region (47). In vivo, these 
fragments are released fi-om the parathyroid glands even when secretion of the intact PTH-
(1-84) is suppressed by high plasma Ca concentrations (47). It is not known, however, 
whether or not these fragments have any true biological activity in vivo. For the purposes of 
this review, PTH is defined as hormone fragments containing the putative biologically active 
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1-27 a.a. region (including the intact 1-84 a.a. hormone), and PTH receptors refer to the 
receptors for these fragments. 
The PTH receptor is a plasma membrane glycoprotein with asparagine-linked 
oligosaccharides (119). It is linked to a guanine nucleotide triphosphate-binding protein (G-
protein) (26,120, 121), and evidence shows that transduction of the PTH signal from the 
cell surface receptor may involve both PKA and PKC signal transduction pathways (122), 
Vitamin D-Dependent Ca-Binding Proteins 
The CaBP-9K and CaBP-28K belong to the troponin-C superfamily of proteins 
(58). They are highly conserved across species and occur in highest concentration in 
several Ca-transporting tissues, such as kidney distal tubules, placenta, and intestine (58). 
They also are found in brain, peripheral nervous system, pancreas, parathyroid gland, and 
bone, although at much lower concentrations (58, 123, 124). Whereas induction of CaBP-
9K and CaBP-28K is dependent on l,25(OH)2D3 in the tissues where they are most 
abundant (13, 58, 123, 125), CaBP-28K is present in the brain in the absence of 
1,25(0H)2D3 (58, 123, 125), suggesting alternate functions in this tissue. This review will 
focus on the role of CaBP-9K and CaBP-28K in regulation of Ca homeostasis, however. 
Both CaBP-9K and CaBP-28K are found in avian intestine and mouse kidney. In 
other mammals, such as rat and pig, however, CaBP-9K is present in intestine but not 
kidney, and CaBP-28K is found in kidney but not intestine (58). The CaBP-9K also has 
been found in rat osteoblast, osteoclast, and bone matrix, where its presence is dependent 
on vitamin D (126). The l,25(OH)2D3 has been shown to modulate rat intestinal CaBP-9K 
gene expression in two ways. The first is by rapid stimulation of transcription, seen within 
15 min of treatment and peaking at one h (13). The second is a post-transcriptional 
stabilizing effect, which prevents degradation of the CaBP-9K transcript (13). This 
stabilization accounts for the observed accumulation of CaBP-9K mRNA several hours after 
1,25(0H)2D3 treatment. 
The CaBP-9K and CaBP-28K bind Ca with high affinity in "EF hand" structures 
and undergo conformational change when Ca binds (58). Although not well defined, their 
function seems to be to enhance vitamin D-dependent transcellular Ca transport (58, 62, 63, 
65), and they are frequently present in tissues also containing a plasma membrane ATP-
dependent Ca pump (127, 128,129, 130). The CaBP-28K in avian intestine and the CaBP-
9K in rat intestine are distributed similarly to the plasma membrane Ca pump (58, 129, 
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131). Correlations have been demonstrated between l,25(OH)2D3 induction of CaBP-9K 
and CaBP-28K and the rate and time course of Ca transport (58,132). The amount of 
CaBP-9K in rat and pig intestine, as well as the efficiency of Ca absorption, increases in 
response to a Ca-deficient diet (133,134). The basolateral membrane of chick intestinal 
enterocytes contains an ATP-dependent Ca pump, which has been shown to be initially 
phosphorylated, and then quantitatively increased after dosing chicks with l,25(OH)2D3 
(63,132). The basolateral membrane of rat renal distal tubules also contains an ATP-
dependent Ca pump (58, 127). Interestingly, the CaBP-28K is confined exclusively to the 
distal tubule and co-localizes with this pump (127). In the proximal tubule, Ca and sodium 
(Na) transport is a coupled process. In the distal tubule, however, Ca and Na transport can 
be dissociated, and Ca transport proceeds against much larger concentration and electrical 
gradients (127). Whereas 50-60% of filtered Ca is reabsorbed by the proximal tubule, the 
10% reabsorbed in the distal tubule is the fraction regulated by PTH (127), implying a 
greater physiological importance than mere quantity may suggest. 
The CaBP-9K and CaBP-28K have been hypothesized to act as buffers for 
intracellular Ca, but their response to dietary Ca changes is inconsistent with the activity of a 
buffer (58). Another hypothesis is that CaBP-9K and CaBP-28K shuttle Ca from the 
intestinal brush border to the basolateral membrane (135). This assumes Ca uptake occurs 
through endocytic vesicles. The Ca then would be transported in lysosomes through the cell 
along microtubules to the basolateral membrane, where it would undergo exocytosis. 
Evidence for this mechanism comes from the regulatory effect of l,25(OH) on a-tubulin 
mRNA expression (135). In a time course corresponding to that of enhanced vesicular Ca 
transport, four tubulin isotypes (including a-tubulin) were increased in microtubules 
isolated from intestinal epithelium of chicks treated with l,25(OH)2D3. Glucocorticoids, 
which suppress l,25(OH)2D3-stimulated Ca transport, decreased the quantity of total 
tubulin rather than altering specific isotypes (135). Additionally, CaBP-9K and CaBP-28K 
may be involved in intracellular signalling pathways. The presence of CaBP-28K increases 
the release of Ca from mitochondria in greater amounts than could be bound by the CaBP-
28K (136). 
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Age Effects on Factors Involved in Regulation of Bone Mineral Homeostasis 
Vitamin D 
Concentrations of l,25(OH)2D3 in plasma have been shown to decline with aging in 
humans and several animal species (27, 137, 138,139). The defect seems to be in 
decreased activity of the kidney la-hydroxylase enzyme (28). When treated with PTH to 
stimulate l,25(OH)2D3 synthesis, no change was seen in elderly osteoporotic patients, 
whereas young healthy adults had almost doubled l,25(OH)2D3 concentrations (28). 
Seasonal variations have been shown in plasma concentrations of l,25(OH)2D3 and 
25(OH)D3, with decreases in winter months when daylight hours are fewer (25, 137). The 
decreased concentrations of 25(OH)D3 were even lower in older adults (mean age 78 yr) 
than in young adults (137). 
The VDR mRNA first appears in rat intestine at about 3 wk of age, the same age at 
which intestinal Ca transport increases (140, 141). In kidney, VDR mRNA is induced 
sometime between birth and one wk of age (141). Both the VDR and its mRNA decline in 
rat intestine with aging after about one mo of age (138,142,143). The VDR also declines 
with aging in rat bone (142). The apparent affinity of intestinal and bone VDR for 
1,25(0H)2D3 remained unchanged (138, 142). In contrast, the VDR content of kidney 
does not change with aging, but the affinity of kidney VDR for DNA-cellulose has been 
shown to decline in aging (144). This decline in VDR affinity for DNA is not seen in 
duodenum, however (138, 144). Two different VDR bands (50K and 52K) were detected 
by immunoblotting in kidney, but only a single 52K band was detected in duodenum (144). 
The apparent size difference between the bands may be the result of phosphorylation (85, 
99). The 50K form elutes from DNA-cellulose at higher salt concentrations than the 52K 
form and is decreased in old rats (144). 
Parathyroid Hormone 
Plasma PTH concentration is chronically elevated with aging (25,137, 139,145, 
146, 147), and renal PTH binding sites are decreased in old animals (145, 148, 149). 
Stimulation of renal Na/Ca exchange by PTH, stimulation of adenylate cyclase activity by 
PTH, and activity of Gg and G, proteins, as detected by ADP-ribosylation, also are 
decreased in aging (145, 149). Parathyroid hormone increased synthesis of 1,25(0H)2D3 
in renal slices from young (3-mo-old) rats but had no effect in renal slices from 12- to 24-
mo-old rats (150, 151). Parathyroidectomy can partially negate these age effects. 
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suggesting that the elevated plasma PTH concentrations down-regulate renal PTH receptors, 
leading to the blunting of kidney response to PTH in aging (148, 149,151). 
Clearance of PTH is not changed by aging, so increased PTH concentrations must 
be caused by increased secretion (152). Evidence shows that perhaps the "set point" of Ca 
concentration for PTH release increases with aging (146,152). That is, PTH can be 
secreted at higher plasma Ca concentrations than those that usually stimulate its secretion. 
Age-related changes in regulation of secretion by Ca also have been shown for CT (146, 
153). Thyroid and parathyroid glands from old (24- to 27-mo-old) rats secreted more PTH 
and CT than did glands from young (2- to 3-mo-old) or adult (12- to 13-mo-old) rats (146, 
153). When exposed to 2.5 mM Ca, suppression of PTH secretion and stimulation of CT 
secretion occurred to a lesser degree in thyroid and parathyroid glands from old rats than 
from young rats (146). Dietary Ca depletion results in increased plasma PTH 
concentrations in young rats, but not in adult or old rats, who have greater plasma PTH 
concentrations compared with young rats regardless of dietary Ca content (147). 
Interestingly, food restriction suppresses increased PTH (153, 154) and CT (153) secretion 
as well as delaying decreases in plasma 25(OH)D3 and l,25(OH)2D3 and bone loss that 
occur with aging (153). 
Vitamin D-Dependent Ca-Binding Proteins 
Intestinal Ca absorption and the ability to adapt to a Ca-deficient diet decrease with 
age in rats and humans (12, 30, 155, 156, 157,158), probably at least in part as a result of 
decreased production of l,25(OH)2D3 (151, 159), which stimulates uptake of dietary Ca by 
the intestine (64, 65). The decrease in absorption is specific for Ca and is not because of 
decreased size of intestinal epithelial cells or decreased total cell number (29,160). Aging 
also results in accelerated Ca turnover rate, with increased Ca excretion in feces and urine 
(161). 
Both kidney CaBP-28K and intestinal CaBP-9K and their mRNAs decrease with 
aging (157,160, 162). In cultured rat renal tubules, treatment with l,25(OH)2D3 induced 
CaBP-28K to a greater extent in tubules from adult (10- to 12-mo-old) and old (20- to 24-
mo-old) rats than in tubules from young (1-mo-old) rats (163). These results imply that the 
in vivo decrease in kidney CaBP-28K seen with aging is probably a result of decreased 
plasma l,25(OH)2D3 concentrations rather than a lack of responsiveness to l,25(OH)2D3. 
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In intestine, l,25(OH)2D3 treatment increased Ca transport to a lesser extent in old rats 
compared with young rats (156, 164). 
In isolated rat intestinal membrane vesicles, CaBP-9K decreased from 3 to 24 mo of 
age (160). Although ATP-dependent Ca uptake did not decrease until between 12 and 24 
mo of age, it was much greater in 3-mo-old rats compared with adults. In the absence of 
ATP, no age difference was observed. The apparent affinity of vesicles for Ca did not 
change with age, but the apparent maximal Ca uptake capacity decreased (155, 160). In 
another experiment, young (6-wk-old) and adult (12-mo-old) rats were made vitamin D 
deficient by feeding a 0.8% strontium diet (12). They then were given oral doses of 
different amounts of l,25(OH)2D3, and intestinal Ca active transport and CaBP-9K content 
were measured. Young rats responded with greater stimulation of active Ca transport 
compared with adult rats for every dose of l,25(OH)2D3 examined (12). Induction of 
CaBP-9K was similar for both young and adult rats. 
Gender and Sex Hormone Effects on Factors Involved in 
Regulation of Bone Mineral Homeostasis 
Few studies have been done comparing males and females in regard to regulation of 
Ca homeostasis, although the specific roles of estrogens and androgens are now being 
studied more closely. 
Calcium and PTH concentrations in plasma follow circadian rhythms, which are 
different in men and women (165). Calcium concentrations are lower in women than in 
men in the early morning. Calcium excretion decreases at night in both men and women, 
but more so in men, and the percentage reduction is greater. Secretion of PTH increases at 
night in botii sexes, but increases earlier and to a greater extent in men. Because of these 
differences, women may be more dependent on dietary Ca intake than are men to maintain 
Ca homeostasis. Although differences in Ca excretion between men and women were small 
(165), daily differences of about 20 mg Ca/d over decades may contribute to gender 
differences in rate of bone loss. 
Plasma Ca concentrations increase from 4 to 12 mo of age in vitamin D-deficient 
female but not in vitamin D-deficient male rats, and vitamin D-deficient females live longer 
than do vitamin D-deficient males (166). It was hypothesized that this age response may be 
a result of females having greater circulating concentrations of prolactin, a known stimulator 
of intestinal Ca absorption (166). Contrary to expected results, however, prolactin 
17 
treatment stimulated passive Ca uptake in isolated intestinal cells only from vitamin D-
deficient male and not from vitamin D-deficient female rats (166). 
Estrogen increases nuclear VDR in rat liver, decreases nuclear VDR in rat kidney, 
and has no effect on nuclear VDR in rat intestine (167). Ovariectomized women, however, 
show a blunted response of intestinal Ca absorption to l,25(OH)2D3, which can be 
prevented by estrogen replacement (168). Because estrogen does not affect intestinal VDR 
content (169), these data support the hypothesis for a vitamin D-independent action of 
estrogen on intestinal Ca absorption (168). Estrogen receptors are present in parathyroid 
tissue and thyroid C cells, and treatment of ovariectomized rats with 17|3-esti*adiol stimulates 
expression of the mRNAs for PTH and CT (170). The combined anabolic effects of PTH 
and CT on bone provide an indirect pathway for estrogen action in prevention of bone loss 
(170). 
Estrogen has direct effects on bone cells in vitro (23, 46), and estrogen receptors 
have been demonstrated in bone cells both in vivo and in vitro (23, 48,171). Nuclear 
binding of estrogen is steroid-specific, saturable, and cell-type specific (23, 48). In bone 
cells in vitro , estrogen may exert anticatabolic effects by decreasing PTH receptor 
responsiveness and may exert anabolic effects by stimulating matrix synthesis and cell 
proliferation (46, 171). In osteoblasts in vitro, 17p-estradiol inhibits the expression of 
interleukin-6 (IL-6) and IL-6 mRNA induced by the bone resorbing cytokines interleukin-1 
(IL-1) and tumor necrosis factor a (TNFa) (172). The IL-6 stimulates osteoclast 
development, so, bone loss caused by estrogen depletion may be because of a loss of 
inhibition of these bone resorbing factors (172). Estrogen enhances l,25(OH)2D3 action in 
rat osteoblast-like osteosarcoma cells by increasing VDR number (169), and also induces 
progesterone receptors and nuclear binding of progesterone in normal cultured human 
osteoblast-like cells (48). Estrogen receptors are present in osteoclasts as well as in 
osteoblasts (173). In vitro, estrogen decreases resorption of bone particles, and decreases 
lysozyme protein concentrations and the expression of lysosomal protein mRNA in 
osteoclasts (173). These findings suggest yet another mechanism by which estrogen acts to 
prevent bone loss in vivo (173). 
Androgens also have direct effects on bone cells (24,45, 174). Specific androgen 
binding and androgen receptor mRNA have been demonstrated in bone cells in vitro (24). 
In human osteoblast-like osteosarcoma cells, androgens decrease cell proliferation and 
increase transcripts for ai(I)-procolIagen and transforming growth factor-}) (24). 
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Testosterone deficiency in humans (175, 176) and castration in rats (177) causes marked 
bone loss, likely through increased resorption (178). Additionally, pharmacologic doses of 
a 19-nortestosterone and a 17a-hydroxyprogesterone independently influence bone 
formation and resorption and enhance 17p-estradiol stimulation of endosteal bone formation 
in the mouse (45). Testosterone and progesterone also inhibit expression of IL-6 by 
osteoblasts, as does nfJ-estradiol (172), although twice the effective concentration of 17p-
estradiol was required for this effect (172). These pharmacological effects of testosterone 
and progesterone may be the result of non-specific binding with estrogen receptors. 
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The aging process changes many factors involved in regulation of bone mineral 
metabolism, including concentrations of 1,25-dihydroxyvitamin D3 [l,25(OH)2D3] and 
parathyroid hormone (PTH) in plasma, and of l,25(OH)2D3 receptors (VDR), vitamin D3-
dependent calcium binding proteins (CaBP-28K and CaBP-9K), and the la,25-
dihydroxyvitamin D-24-hydroxylase (24-hydroxylase) in target tissues. These changes may 
affect the process which results in age-associated disease, such as osteoporosis. 
Osteoporosis occurs much more frequently in females than in males, in part because of 
changes that occur at menopause. Females attain lower peak bone density than do males. 
The extent of adverse effects of age-related bone loss is less if peak bone density is greater. 
In the present study, various physiological factors in both female and male Fischer 344 rats 
of different ages (1, 2.5, 6, and 18 mo) were compared. Plasma l,25(OH)2D3 
concentrations decreased with age in rats of both genders. Abundance of the CaBP-28K 
and its mRNA in kidney, and CaBP-9K and CaBP-9K mRNA in intestine also decreased (P 
<0.05) with age in both male and female rats. These decreases would be expected with low 
plasma l,25(OH)2D3 concentrations. Kidney 24-hydroxylase activity and 24-hydroxylase 
mRNA content were elevated significantly in 18-mo-old males and females, compared with 
younger ages. These data suggest increased renal catabolism of l,25(OH)2D3 may be 
responsible for low plasma l,25(OH)2D3 concentrations observed in the older animal. 
Most differences between males and female rats were found at 2.5 mo of age, which 
represents sexual maturity for rats. Plasma PTH concentrations, plasma l,25(OH)2D3 
concentrations, 24-hydroxylase enzyme activity and 24-hydroxylase mRNA content in 
kidney, abundance of 24-hydroxylase mRNA in intestine, and amount of CaBP-9K and 
CaBP-9K mRNA in intestine were greater (P <0.05) in males than in females at 2.5 mo of 
age. The lower plasma l,25(OH)2D3 concentrations in females help to explain observed 
gender differences in the expression of genes stimulated by l,25(OH)2D3. The combined 
effects of these gender differences at ages when peak bone density is being developed may 
contribute to the greater incidence of osteoporosis in females compared with males. 
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INTRODUCTION 
Involutional osteoporosis is an age-related disorder characterized by an absolute 
decrease in bone mass, causing susceptibility to bone fractures (1). The disease affects an 
estimated 15-20 million men and women in the United States (1), although women have a 
much greater risk (1,2). Of women over 65, one-third will suffer vertebral fractures during 
their lifetime (2). 
Females are at a greater risk for osteoporosis than are males, in part because of 
accelerated bone loss that occurs after menopause. Females also attain lower peak bone 
mass than do males, and lose a greater percentage of bone over the lifetime. Estrogen 
depletion is related to development of osteoporosis in females. Estrogens and androgens 
have direct effects on bone cells in vitro (7,8), and estrogens modulate l,25(OH)2D3 
activity (9, 10), but littie is known about the specific mechanisms that lead to the 
development of osteoporosis. Not everyone with estrogen deficiency, however, develops 
osteoporosis (2). This fact suggests that other factors may be responsible for changes in 
calcium (Ca) absorption and bone mineral maintenance. 
Peak bone density is achieved by about age 30-35 yr (3,4, 5). Age-related bone 
loss, which begins soon after (3, 4, 5), is more problematic if less bone is present. A loss 
of 30% of peak bone density will lead to fracture susceptibility if peak bone density was 
low, but may not be a problem if peak bone density was great. Although many cases of 
osteoporosis in women are related to changes that occur at menopause (3), the slow phase 
of bone loss begins well before menopause (6). For these reasons, it is important to study 
factors involved in the regulation of bone mineral homeostasis throughout the life span, and 
not just in senescence, when bone loss has already occurred. Prevention of the disease 
would be preferable to treatment after the fact. 
The active hormonal form of vitamin D3, 1,25-dihydroxy vitamin D3 
[1,25(0H)2D3], plays a major role in regulation of bone mineral metabolism (11). Both 
formation and catabolism rates determine the circulating concentrations of l,25(OH)2D3. In 
the kidney, parathyroid hormone (PTH) induces the activity of 25-hydroxyvitamin D-la-
hydroxylase (1 «-hydroxylase), and suppresses la,25-dihydroxyvitamin D-24-hydroxylase 
(24-hydroxylase) activity (12, 13). PTH does not down-regulate 24-hydroxylase in the 
intestine (14). The l,25(OH)2D3 induces 24-hydroxylase activity in both kidney and 
intestine (15, 16, 17, 18). Intracellular l,25(OH)2D3 receptors (VDR) mediate the effects 
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of 1,25(0H)2D3 in the major target tissues of kidney, bone, and intestine (11). Changes in 
VDR expression may affect target tissue responsiveness. The l,25(OH)2D3 up-regulates its 
receptor in vitro (19, 20). Vitamin D-dependent Ca binding proteins (CaBP-28K and 
CaBP-9K), which seem to be involved in regulation of Ca absorption, also are regulated by 
1,25(0H)2D3 through its receptor (21, 22). 
During the aging process, changes occur in many of the factors involved in 
regulation of Ca homeostasis. Plasma PTH concentration is elevated chronically (23,24), 
whereas renal PTH responsiveness decreases (24). Intestinal Ca absorption decreases (25, 
26), and production of l,25(OH)2D3 in the kidney decreases (27, 28). 
Male and female rats were compared to determine whether any gender differences 
exist in the factors studied. The purpose of this study was to more carefully examine factors 
involved in the regulation of bone mineral homeostasis at ages representative of various 
stages of the life span. Specifically, we examined gene products regulated by 
1,25(0H)2D3, including the VDR, CaBP-28K and CaBP-9K, and the 24-hydroxylase 
enzyme. 
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MATERIALS AND METHODS 
Materials 
Vitamin D metabolites [25(OH)D3, l,25(OH)2D3, 24,25(OH)2D3, 
1,24,25(0H)3D3, and l,25,28(OH)3D2] were gifts from Milan Uskokovic (Hoffmann-
LaRoche, Inc., Nutley, NJ). Complementary DNA (cDNA) for rat VDR was provided by 
Dr. Wesley Pike (Ligand Pharmaceuticals, San Diego, CA). Mouse CaBP-28K cDNA was 
a gift from Sylvia Christakos (University of Medicine and Dentistry of New Jersey, 
Newark, NJ). M. Elizabeth Bmns (University of Virginia Medical School, Charlottesville, 
VA) provided the cDNA for mouse CaBP-9K. Kyuichiro Okuda (Hiroshima University 
School of Dentistry, Hiroshima, Japan) provided the cDNA for rat 24-hydroxylase. The a-
[32p]-dCTP (3,000 Ci/mmol, 10 mCi/ml) and Y-[32p]-ATP (4,500 Ci/mmol, 10 mCi/ml) 
was purchased from Amersham Corp. (Arlington Heights, IL). 01igo-d(T)|g was from 
Pharmacia (Piscataway, NJ). All other chemicals were of reagent grade or better. 
Animals 
Animal studies were conducted in accord with NIH Guidelines for the Care and Use 
of Laboratory Animals, and specific animal protocols were approved by the National Animal 
Disease Center Animal Care and Use Committee. Six male and six female Fischer 344 rats 
of each age were used. Eighteen-mo-old rats were purchased from the NIH (Bethesda, 
MD) aging colony. Rats of all other ages were purchased from Harlan-Sprague-Dawley 
(Madison, WI). Rats were maintained on Teklad (Madison, WI) stock diet for one wk after 
arrival. Final ages were 4-wk-, 2.5-mo-, 6-mo-, and 18-mo-old. Rats were anesthetized 
with C02:02 (1:1) and decapitated. Blood was collected for analysis of plasma Ca, PTH, 
and 1,25(0H)2D3. Mucosa was scraped from the proximal 20 cm of the small intestine. 
One-half was used to assay VDR content, and one-half was frozen immediately in liquid N2 
for later RNA extraction. Kidneys also were collected: one for assay of VDR concentration, 
and one frozen in liquid N2 for RNA extraction. 
We also compared 2.5- and 18-mo-old male and female Fischer 344 rats for 
response to treatment with 1,25(0H)2D3. Rats were fed a purified diet (Teklad) containing 
1% Ca for one wk, then were injected intraperitoneally (i.p.) with 72 ng/kg body weight of 
1,25(0H)2D3 (in 5% ethanol, 95% propylene glycol) 6 hours before death. Mucosa from 
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the proximal 20 cm of the small intestine was either assayed for 24-hydroxylase activity or 
frozen in liquid N2 for later RNA extraction. Kidneys also were collected for later RNA 
extraction, or cortices were removed and assayed for 24-hydroxylase activity. 
VDR Assay 
Kidneys or intestinal mucosa were minced and washed in ice cold Tris/NaCl buffer 
(10 mM Tris, pH 7.4, 50 mM NaCl) with 50 KlU/ml proteinase inhibitor (Trasylol, Mobay 
Chemical Corp., New York, NY). Tissue then was homogenized (20% w/v) in 500 mM 
KTD (500 mM KCl, 10 mM Tris, pH 7.4, 5 mM dithiothreitiol, 200 |ig/ml soybean trypsin 
inhibitor) (29) and centrifuged at 230,000 X g. Aliquots (50 |il) of the resulting supernatant 
(cytosol) were incubated with 8 nM [3H]-1,25(0H)2D3 ± 100-fold excess of l,25(OH)2D3 
in triplicate at 4 C for 16 h to estimate VDR binding sites. Bound and free hormone were 
separated using hydroxyapatite. All VDR assays were corrected for non-specific binding. 
Cytosol protein concentration was determined by the Bradford method, with a bovine serum 
albumin (BSA) standard (30). 
CaBP Assays 
Kidney and intestinal cytosol s were prepared as described for the VDR assay. 
Kidney cytosol then was analyzed for CaBP-28K content by radioimmunoassay as 
previously described (31). Intestinal cytosol from 1-, 2.5-, 6-, and 18-mo-old male and 
female rats first was equilibrated into 10 mM Tris buffer, pH 7.4 by using PD-10 sepharose 
columns (Pharmacia) and then lyophilized in a Speed Vac Concentrator (Savant Instruments, 
Inc., Farmingdale, NY). Lyophilized samples were redissolved in 1 ml of 10 mM Tris, pH 
7.4 and assayed for protein concentrations (30). Intestinal CaBP-9K content was analyzed 
(32) by using specific polyclonal antisera to CaBP-9K (33). 
Intestinal 24-Hydroxylase Assay 
Intestinal 24-hydroxylase activity was determined by measuring the amount of [^H]-
1,24,25(0H)3D3 produced during incubation of intestinal mucosa homogenates with [%]-
1,25(0H)2D3 (34). Intestinal mucosa was homogenized (5% w/v) in ice cold 0.25 M 
sucrose, 40 mM HEPES pH 7.4,2 mM dithiothreitol (DTT). Aliquots of homogenate were 
25 
incubated for 5-15 min at 37 C with 6 |iCi [3H]-1,25(0H)2D3, 7.7 mM glucose-6-
phosphate, 7 mM ATP, 56 mM nicotinamide, 147 |iM NAD+, 130 fiM NADP+, 2.6 mM 
succinate, 35 mM KHPO4, 2.8 mM MgCl2, 35 mM KCl, 0.07 U/ml glucose-6-phosphate 
dehydrogenase, 0.30 U/ml alcohol dehydrogenase (18, 34). An additional 144 nM 
1,25(0H)2D3 was added to reactions with homogenates from animals treated with 
1,25(0H)2D3. The reaction was stopped by addition of 3.8 volumes of MeOH:MeCl2 
(2:1). An aliquot of 1,25,28(0H)3D2 was added to each tube as a marker for the efficiency 
of extraction with MeCl2. Extracts were dried in a SpeedVac Concentrator (Savant 
Instruments, Inc., Farmingdale, NY) and stored under N2 at -20 C. For HPLC analysis, 
extracts were resuspended in the column running solvent [hexane:isopropanol:MeOH 
(88:10:2)], and run over a 4.6 mm x 250 mm Spherisorb NH2 column (Isco, Inc., Lincoln, 
NE) at a rate of 2 ml/min. One-min eluate fractions were collected, dried, and peaks 
were quantitated by using liquid scintillation counting. Recovery of l,25,28(OH)3D2 was 
measured by UV absorbance at 254 nm. Protein concentrations were measured in intestinal 
homogenates by the Bradford method, with a bovine serum albumin (BSA) standard (30). 
Amount of -1,24,25(0H)3D3 produced per min per mg protein was calculated and 
corrected for recovery of l,25,28(OH)3D2. 
Kidney 24-Hydroxylase Assay 
Kidney 24-hydroxylase activity was determined by measuring the amount of 
24,25(0H)2D3 produced during incubation of kidney cortex homogenates with 25(OH)D3 
(35). Kidney cortex was homogenized (10% w/v) in ice cold 0.25 M sucrose, 50 mM 
HEPES, pH 7.4, and centrifuged at 12,900 X g. The resulting pellet was resuspended by 
homogenizing (10% w/v) in ice cold solution of 0.15 M sucrose, 40 mM HEPES, pH 7.4, 
2 mM MgCl2, and 10 mM malate. Aliquots of homogenate were incubated for 15 min at 37 
C with 15.6 jiM 25(0H)D3. The reaction was stopped by addition of 1 volume of 
MeOH:MeCl2 (2:1). An aliquot of [3H]-24,25(0H)2D3 was added to each tube as a marker 
for the efficiency of extraction with MeCl2. Extracts were dried in a SpeedVac Concentrator 
(Savant Instruments, Inc.) and stored under N2 at -20 C. For HPLC analysis, extracts were 
resuspended in the column running solvent [hexane:MeCl2:EtOH:acetonitrile (90:6:3:1)], 
and run over a 4.6 mm x 250 mm Spherisorb NH2 column (Isco, Inc.) at a rate of 2 ml/min. 
One-min eluate fractions were collected, and an aliquot was analyzed for recovery of pH]-
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24,25(0H)2D3 by using liquid scintillation counting. Elution time for 24,25(OH)2D3 was 
determined by UV absorbance at 254 nm of a 24,25(OH)2D3 standard. Fractions 
containing the 24,25(OH)2D3 peak were pooled and concentrated. A protein binding assay 
(36) was used to quantitate 24,25(OH)2D3 in the peak. Protein concentrations were 
measured in kidney cortex homogenates by the Bradford method, with a BSA standard 
(30). Amount of 24,25(0H)2D3 produced per min per mg protein was calculated and 
corrected for recovery of [3H]-24,25(0H)2D3. 
Northern and Slot Blot Analyses 
An acid guanidinium thiocyanate-phenol-chloroform extraction was used to isolate 
RNA from kidney and intestinal mucosa (37). Poly(A)+ RNA then was prepared by oligo-
d(T)-cellulose chromatography. Poly(A)+ RNA (10-20 iig) was separated on a 1.2% 
formaldehyde-agarose gel and transferred to an Optibind reinforced nitrocellulose membrane 
(Schleicher and Schuell, Keene, NH) or to a Magna NT nylon membrane (Micron 
Separations Inc., Westboro, MA) for Northern blots. For slot blot analysis, poly(A)+ RNA 
(1.25-5 |ig) was blotted onto Optibind membranes by using a Minifold II slot blot apparatus 
(Schleicher and Schuell). The RNA was cross-linked to the membranes by irradiation with 
a Stratagene UV Stratalinker (Stratagene Cloning Systems, La Jolla, CA) or by a 5-min 
exposure to UV light. Restriction enzyme digestion was used to obtain a 1.7 kb rat VDR 
cDNA insert from the EcoRI site of pIBI76 (38), a 1.2 kb mouse CaBP-28K cDNA insert 
from the EcoRI site of pIBI76 (39), a 0.2 kb mouse CaBP-9K cDNA insert from the EcoRI 
site of Bluescribe (40), and a 3.4 Kb rat 24-hydroxylase cDNA insert from the EcoRI site of 
pUC19 (41). A random primer oligolabeling kit (Pharmacia) was used to label the cDNA to 
a specific activity of 10^-10^ dpm/p.g of DNA. Membranes were prehybridized for 20-60 
min (Optibind), or for 1-2 h (Magna NT), at 42 C in 5X SSPE (SSPE = 0.18 M NaCl, 10 
mM Na2P04, 1 mM EDTA, pH 7.4), 50% formamide, 5X Denhardt's reagent [IX 
Denhardt's = 0.02% Ficoll (type 400), 0.02% polyvinylpyrrolidone, 0.02% BSA (fraction 
V)], 0.5% sodium dodecyl sulfate (SDS) and 100 |ig/ml denatured herring sperm DNA. 
Hybridization was carried out overnight at 42 C in fresh prehybridization buffer plus 250 jig 
of transfer RNA as a carrier and 1-5 X 10^ cpm/ml of 32p-iabeled cDNA probe. 
Membranes were washed twice for 10 min at room temperature in 2X SSPE/0.1% SDS and 
then twice for 10 min at room temperature in O.IX SSPE/0.1% SDS. For CaBP-9K, and 
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CaBP-28K probes, membranes sometimes were washed twice for 10 min at room 
temperature in 2X SSPE/0.1% SDS only. Imaging and quantitation of bands was done 
with an AMBIS Radioanalytic Imaging System (AMBIS, Inc., San Diego, CA). 
Autoradiography was carried out at -70 C for 12-168 h with XOMAT X-ray film (Eastman 
Kodak Co., Rochester, NY) with an intensifying screen. To normalize for the amount of 
poly(A)+ RNA loaded, membranes were probed with a pd(T)ig probe (42). The pd(T)ig 
was labeled with either y-[^^P]-ATP, by using a DNA 5'-terminus labeling system (BRL 
Laboratories Life Technologies, Inc., Gaithersburg, MD), or with a-[32p]-dCTP, by using 
a DNA 3'-end-labeling system from Promega (Madison, WI). Membranes were 
prehybridized for 10 min at room temperature in 5X SSPE and then hybridized for 1-2 h at 
room temperature in 5X SSPE and 5X Denhardt's reagent plus 200 pmol of [32p]-labeled 
pd(T)i8 per 11 X 14 cm membrane. Washing was four times for 5 min at room temperature 
in 2X SSPE for the 5'-end labeled probe or twice for 10 min at room temperature in 2X 
SSPE/0.1% SDS for the 3'-end labeled probe. Imaging, quantitation, and autoradiography 
were performed as described for cDNA probes. 
Other Analyses 
Plasma PTH concentration was measured with an N-terminal specific 
radioimmunoassay (Nichols Institute Diagnostics, San Juan Capistrano, CA). Atomic 
absorption spectrophotometry was used to determine plasma Ca content (43). Plasma 
extracts were assayed for l,25(OH)2D3 as described previously (44). Statistical differences 
were determined by using Analysis of Variance and Bonferroni Multiple Comparisons tests. 
Values were considered to be significantly different when P <0.05. 
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RESULTS 
Expression of l,25(OH)2D3-reguIated genes was examined in kidneys of male and 
female rats from weanlings to senescence. As seen in Figure 1, kidney VDR concentration 
did not change over the age span studied. The abundance of VDR mRNA in kidney was 
similar to the VDR protein (Fig. 1). No gender differences were found in VDR mRNA or 
VDR protein in kidney, except at 2.5 mo of age, when females had more (P <0.05) VDR, 
but not VDR mRNA, in kidney than did males (Fig. 1). 
Kidney CaBP-28K concentration decreased (P <0.05) with age in both males and 
females (Fig. 2). The message for CaBP-28K also declined with age in both males and 
females (Fig. 2). The magnitude of decline in renal CaBP-28K mRNA was less in females 
than in males, however, because of the lower amounts present in kidneys of females 
compared with males at one mo of age (Fig. 2). 
Expression of the mRNA for the l,25(OH)2D3-catabolizing enzyme, 24-
hydroxylase, increased dramatically (P <0.05) with aging in kidneys of both male and 
female rats (Fig. 3). This age increase was greater (P <0.05) in males than in females (Fig. 
3). Additionally, abundance of 24-hydroxylase mRNA in kidney was greater (P <0.05) in 
males than in females at 2.5 and 6 mo of age (Fig. 3). Renal 24-hydroxylase enzyme 
activity also increased (P <0.05) with aging in both males and females (Table I). In 
contrast to 24-hydroxylase message abundance, however, the age increase in 24-
hydroxylase activity was not greater in males than in females (Table 1). At sexual maturity 
(2.5-mo-old), males had both greater (P <0.05) renal 24-hydroxylase activity (Table 1) and 
24-hydroxylase mRNA content (Fig. 3) than did females. 
Expression of l,25(OH)2D3-regulated genes also were examined in intestinal 
mucosa of weanling through senescent male and female rats. Intestinal VDR concentration 
decreased (P <0.05) with age for rats of both genders (Fig. 4). The abundance of VDR 
mRNA in intestine followed a similar pattern to that of VDR protein concentration over age 
in both males and females (Fig. 4). Intestinal VDR, but not VDR mRNA, content decreased 
with age to a lesser extent in females compared with males (Fig. 4). 
As seen in Figure 5, intestinal CaBP-9K concentration decreased greatly (P <0.05) 
with age in both males and females. Correspondingly, the abundance of intestinal CaBP-
9K mRNA also decreased (P <0.05) with age in rats of both genders (Fig. 5). These 
decreases in CaBP-9K and CaBP-9K mRNA content of intestine were not as dramatic in 
FIGURE 1. Effect of age and gender on kidney VDR and VDR mRNA expression. 
Values for VDR are the mean ± SEM for six rats. VDR mRNA values are 
from slot blots and are presented as a fraction of the value for 1-mo-old 
males (control), after correction for background and normalization to 
pd(T)ig. Quantitation was done by using an AMBIS Radioanalytic Imaging 
System (AMBIS, Inc., San Diego, CA). * Indicates means significantly 
(P <0.05) different between male and female rats of the same age. 
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FIGURE 2. Effect of age and gender on kidney CaBP-28K and CaBP-28K mRNA 
expression. Values for CaBP-28K are the mean ± SEM for six rats. CaBP-
28K mRNA values are from slot blots and are presented as a fraction of the 
value for 1-mo-old males (control), after correction for background and 
normalization to pd(T)ig. Quantitation was done by using an AMBIS 
Radioanalytic Imaging System (AMBIS, Inc., San Diego, CA). * Indicates 
means significantly (P <0.05) different between male and female rats of the 
same age. 
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FIGURE 3. Effect of age and gender on kidney 24-hydroxylase mRNA. 24-
Hydroxylase mRNA values are from slot blots and are presented as a 
fraction of the value for 1-mo-old males (control) after correction for 
background and normalization to pd(T)ig. Quantitation was done by using 
an AMBIS Radioanalytic Imaging System (AMBIS, Inc., San Diego, CA). 
* Indicates means significantly (P <0.05) different between male and female 
rats of the same age. ° Indicates means significantly (P <0.05) different 
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FIGURE 4. Effect of age and gender on intestinal VDR and VDR mRNA expression. 
Values for VDR are the mean ± SEM for six rats. VDR mRNA values are 
from slot blots and are presented as a fraction of the value for 1-mo-old 
males (control), after correction for background and normalization to 
pd(T)i8. Quantitation was done by using an AMBIS Radioanalytic Imaging 
System (AMBIS, Inc., San Diego, CA). * Indicates means significantly 
(P <0.05) different between male and female rats of the same age. 
Intestine VDR mRNA 










^18 Months 1-j 
1 Month 
5 Months 
^ Months ^ 
v-m-rr-rrww-y^ yj^  
48 Months 
^ f r e rffffrrreÀ ' k 
Intestine VDR 
fmol/mg Protein 
r* © o o 
w o o o o 
FIGURE 5. Effect of age and gender on intestinal CaBP-9K and CaBP-9K mRNA 
expression. Values for CaBP-9K are the mean ± SEM for six rats. CaBP-
9K mRNA values are from slot blots and are presented as a fraction of the 
value for 1-mo-old males (control), after correction for background and 
normalization to pd(T)ig. Quantitation was done by using an AMBIS 
Radioanalytic Imaging System (AMBIS, Inc., San Diego, CA). * Indicates 
means significantiy (P <0.05) different between male and female rats of the 
same age. 
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TABLE 1. Kidney 24-hydroxylase activity in 2.5- and 18-mo-old male and female 
Fischer 344 rats 
2.5 mo 18 mo 
Female 48.8 ± 10.8 392.7 ±98.1» 
Male 144.2 + 29.2b 193.8 + 37.8 
Values are pg 24,25(OH)2D3/min • mg of protein (mean ± SEM for six rats). 
''Means significantly different (P <0.05) between 2.5- and 18-mo-old rats of the 
same gender. 
^Means significantly different (P <0.05) between male and female rats of the same 
age. 
females, however, because females had lesser (P <0.05) amounts of CaBP-9K and CaBP-
9K mRNA at the younger ages than did males (Fig. 5). 
Abundance of the 24-hydroxylase mRNA in intestinal mucosa decreased (P <0.05) 
between one and 18 mo of age in male rats (Fig. 6). Intestinal 24-hydroxylase mRNA 
content was similar between males and females, except at 2.5 mo of age, when females had 
less (P <0.05) 24-hydroxylase mRNA in intestine than did males (Fig. 6). Activity of the 
intestinal 24-hydroxylase enzyme, which is constitutively low unless stimulated, did not 
change with age in rats of either gender (Table 2). Intestinal 24-hydroxylase activity was 
not different between males and females at the detectability limits of the assay used (Table 
2). Male and female rats aged 2.5- and 18-mo-old all responded to an i.p. injection of 
1,25(0H)2D3 with an increase (P <0.05) in intestinal 24-hydroxylase activity (Table 2). 
Eighteen-mo-old females with a greater (P <0.05) increase in intestinal 24-hydroxylase 
activity than did 2.5-mo-old females to l,25(OH)2D3 treatment (Table 2). This age 
difference in response to l,25(OH)2D3 injection was not seen in males (Table 2). The 2.5-
mo-old males treated with l,25(OH)2D3 had greater (P < 0.05) intestinal 24-hydroxylase 
FIGURE 6. Effect of age and gender on intestinal 24-hydroxylase mRNA. 24-
Hydroxylase mRNA values are from slot blots and are presented as a 
fraction of the value for 1-mo-old males (control) after correction for 
background and normalization to pd(T)ig. Quantitation was done by using 
an AMBIS Radioanalytic Imaging System (AMBIS, Inc., San Diego, CA). 
* Indicates means significandy (P <0.05) different between male and female 
rats of the same age. ° Indicates means significantly (P <0.05) different 
between different aged rats of the same gender. 
Intestine 24-HydroxyIase mRNA 
Fraction of Control 
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TABLE 2. Intestinal 24-hydroxylase activity in 2.5- and 18-mo-old maie and female 
Fischer 344 rats injected intraperitoneally with 72 ng/kg of body weight of l,25(OH)2D3 (in 
5% ethanol, 95% propylene glycol) 6 h before death 
Control + 1.25fOH^2P2 
2.5 mo 18 mo 2.5 mo 18 mo 
Female 10.4 + 2.0 8.1 ±0.8 48.8 ± 5.6a 81.9± l l . i a . b  
Male 10.9 ±0.9 14.5 ±2.8 69.4 ± 4.2a, c 54.8 ± 7.7a. c 
Values are pg l,24,25(OH)3D3/min • mg of protein (mean + SEM for six rats). 
^Means significantly different (P <0.05) between treated and untreated rats of the 
same age and gender. 
bMeans significantly different (P <0.05) between 2.5- and 18-mo-old rats of the 
same gender and treatment. 
cMeans significantly different (P <0.05) between male and female rats of the same 
age and treatment. 
activity than did 2.5-mo-old females treated with l,25(OH)2D3 (Table 2). At 18 mo of age, 
however, males treated with l,25(OH)2D3 had lower (P <0.05) intestinal 24-hydroxylase 
activity compared with l,25(OH)2D3-treated females of the same age (Table 2). 
As expected, plasma PTH concentrations increased (P <0.05) with age in both males 
and females (Table 3). Females, however, had lower (P <0.05) plasma PTH concentrations 
at 2.5 mo of age than did males (Table 3). 
In both male and female rats, plasma l,25(OH)2D3 concentrations decreased 
(P <0.05) with age (Table 4). Females had lower (P <0.05) concentrations of plasma 
1,25(0H)2D3 than did males at both 2.5 and 18 mo of age (Table 4). Concentrations of 
1,25(0H)2D3 in plasma increased (P <0.05) similarly in all age groups treated in response 
to 1,25(0H)2D3 injection (Table 4). 
No gender or age differences were found for plasma Ca concentrations. 
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TABLE 3. Plasma PTH concentrations in 2.5- and 18-mo-old maie and female Fischer 
344 rats 
2.5 mo 18 mo 
Female 125.8 ± 16.1 264.2 ± 25.7» 
Maie 220.7 + 20.0b 285.8 + 56.7 
Values are pg PTH/ml of plasma (mean + SEM for six rats). 
^Means significantly different (P <0.05) between 2.5- and 18-mo-old rats of the 
same gender. 
bMeans significantly different (P <0.05) between male and female rats of the same 
age. 
All Northern and slot blots used for quantitation of mRNA abundance were 
normalized by using a pd(T)ig probe. This probe was chosen because P-actin mRNA was 
found to change with age in the tissues examined here (intestinal mucosa and kidney) (Figs. 
Al, A2, A3). For this reason, p-actin cDNA was determined to be an inappropriate probe 
for normalization of quantity of poly(A)+ RNA applied to membranes in aging experiments. 
Poly(A)+ RNA, as measured by probing blots with pd(T)ig, did not change with age in 
either intestinal mucosa or kidney (Fig. A3). See the Appendix for a complete explanation 
and data on choice of probes for normalization in aging studies. 
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TABLE 4. Plasma l,25(OH)2D3 concentrations in 2.5- and 18-mo-old maie and female 
Fischer 344 rats injected intraperitoneally with 72 ng/kg of body weight of 1,25(OH)2D3 (in 
5% ethanol, 95% propylene glycol) 6 h before death 
Control + L25fOH^2% 
2.5 mo 18 mo 2.5 mo 18 mo 
Female 48.7 + 2.3 34.5 ± 4.8a 249.2 + 12.7b 259.3 ± 3.9 ^ 
Male 80.0±7.4c 60.4+ 1.2». c 303.1 ± 15.1^. c 307.2 ± 9.1^. c 
Values are pg l,25(OH)2D3/ml of plasma (mean + SEM for six rats). 
^Means significantly different (P <0.05) between 2.5- and 18-mo-old rats of the 
same gender and treatment. 
•'Means significantly different (P <0.05) between treated and untreated rats of the 
same age and gender. 
cMeans significantly different (P <0.05) between male and female rats of the same 
age and treatment. 
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DISCUSSION 
The extent of adverse effects of age-related bone loss in an individual is dependent in 
part on the absolute peak bone density achieved before net bone loss begins. It is important, 
therefore, to study factors that regulate bone mineral homeostasis at ages when bones are 
developing, as well as at later ages, when bone diseases, such as osteoporosis, cause 
adverse bone loss. Females are more susceptible to osteoporosis, and also achieve lower 
peak bone density compared with males. For these reasons, this study examined factors 
involved in the regulation of bone mineral homeostasis in rats of ages representative of 
various stages of the life span. Both male and female rats were compared to determine 
whether any gender differences exist in the factors studied. Specifically, we examined 
factors involved in regulation of Ca homeostasis whose gene expression is regulated by 
1,25(0H)2D3. 
Kidney CaBP-28K and its mRNA decreased (P <0.05) with age in both male and 
female rats (Fig. 2). Amount of intestinal CaBP-9K and its mRNA also decreased 
(P <0.05) with age (Fig. 5). Similar results were found in male rats by Armbrecht et al (45) 
for changes in the expression of kidney CaBP-28K and intestinal CaBP-9K in aging rats. 
These changes may be a response to the decreased (P <0.05) concentration of plasma 
1,25(0H)2D3 in older rats (Table 4), because l,25(OH)2D3 regulates the expression of 
CaBP-28K and CaBP-9K through its receptor (21, 22). Expression of intestinal CaBP-9K 
is absolutely dependent on the presence of l,25(OH)2D3 (21,22). Additionally, the 
decrease (P <0.05) in intestinal VDR concentration with age (Fig. 4) would contribute to 
decreased expression of CaBP-9K in the intestine, because 1,25(OH)2D3 exerts its effects 
on gene transcription through the VDR (11). These findings also help to explain the decline 
in Ca absorption in the intestine that occurs with aging (25,26), because CaBP-9K is 
involved in this process (21, 22), although the specific mechanism by which the CaBP-9K 
facilitates Ca absorption is unknown. 
Concentration of VDR and abundance of VDR mRNA in intestine also decreased 
(P <0.05) with age in both females and males, but neither changed in kidney (Figs. 1 and 
4). Horst et al, (46) and Koszewski et al. (47) have published similar results for intestinal 
and kidney VDR, respectively, in one- and 18-mo-old male rats. Although kidney VDR 
(Fig. 1) did not decrease with age as did intestinal VDR (Fig. 4), CaBP-28K and its 
message (Fig. 2) did decline with age in kidney. This difference may be explained by a 
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decrease in VDR binding to DNA-cellulose that occurs in kidneys, but not intestine, of aged 
rats (47). The decreased DNA binding capacity of VDR in kidneys of old rats, in addition 
to the age-related decrease in plasma l,25(OH)2D3 concentrations, would likely result in 
decreased stimulation of expression of kidney CaBP-28K. 
Kidney 24-hydroxylase activity (Table 1) and 24-hydroxylase mRNA (Fig. 3) 
increased (P <0.05) with aging in both males and females. An increase in 24-hydroxylase 
activity in the kidney has been shown before in male rats; renal [3H]-24,25(0H)2D3 
production was increased in 13- and 25-mo-old rats compared with that in 2.5-mo-old rats 
(48,49). PTH is a negative regulator of 24-hydroxylase activity (12, 50); so, down-
regulation of PTH receptors seen in old rats (24,51, 52) likely would result in an increase 
in 24-hydroxylase activity by way of decreasing suppression of the enzyme. Plasma 
1,25(0H)2D3, a positive regulator of 24-hydroxylase activity and 24-hydroxylase mRNA 
expression (53,54), was lower (P <0.05) in old rats (Table 4) than in young rats. It seems 
then that the PTH effects must override the effects of l,25(OH)2D3 in this case. The fact 
that the mRNA follows the same pattern as the enzyme activity would suggest that PTH 
regulates the enzyme at the pre-translational level either by regulating transcription or by 
stabilizing the untranslated mRNA. The degree of stimulation of production of cAMP by 
PTH was decreased by 25% in 12-mo-oId male rats compared with 1-mo-old rats (49). 
These results support a decrease in PTH responsiveness in kidney as a reason for increased 
24-hydroxylase expression in older rats. Contrasting results were found by Armbrecht and 
Boltz (55) for changes in kidney 24-hydroxylase mRNA expression as a result of aging. 
They found that the expression of 24-hydroxylase mRNA in kidney was lower in old rats 
throughout a 48-h period after a dose of l,25(OH)2D3. The differences in their results may 
be because the rats in this experiment (55) were first made vitamin D deficient by feeding a 
low Ca, 0.8% strontium diet for 6 d. It is unknown what other physiological effects this 
treatment may have. The physiological state of rats treated in this manner is far from 
normal. Data from this study (55), therefore, are not representative of what is occurring in a 
normal physiological state; so, the observed decrease in l,25(OH)2D3-induced expression 
of kidney 24-hydroxylase mRNA in old rats is irrelevant when used to explain what is 
happening in aging of normal animals. Age-related increases in renal 24-hydroxylase 24-
hydroxylase mRNA suggest that renal catabolism of l,25(OH)2D3 increases in aging 
animals. Therefore, the low plasma l,25(OH)2D3 concentrations observed in the aged 
animal could be the result of increased turnover of l,25(OH)2D3. 
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Intestinal 24-hydroxylase mRNA content declined (P <0.05) with age in both males 
and females (Fig. 6), but no change was seen in activity of the intestinal enzyme at the 
detectability limits of the enzyme assay. Activity of intestinal 24-hydroxylase stimulated by 
an i.p. injection of l,25(OH)2D3 also did not change with age in male rats.(Table 2). 
Plasma l,25(OH)2D3 decreased (P <0.05) with age (Table 4,48, 49) in both sexes. 
Intestine has not been shown to contain PTH receptors; so, it is likely that l,25(OH)2D3 is 
the primary regulator of 24-hydroxylase in this tissue. In fact, PTH inhibits 24-hydroxylase 
mRNA expression stimulated by l,25(OH)2D3 in kidney but not in intestine (14). The 
positive stimulation of 24-hydroxylase expression would decrease with the reduction in 
plasma l,25(OH)2D3 concentration that occurs in aging. The VDR, through which 
1,25(0H)2D3 exerts its transcriptional effects, also decreases with age in the intestine (46). 
A confusing result is that, in females, l,25(OH)2D3-stimulated intestinal 24-hydroxylase 
activity was greater (P <0.05) in 18-mo-old compared with 2.5-mo-old female rats (Table 
2). This age increase in females, but not in males, cannot be explained by regulation of the 
enzyme by l,25(OH)2D3, because plasma l,25(OH)2D3 concentrations decrease (P <0.05) 
with age (Table 4), and are lower (P <0.05) in females than in males at both 2.5 and 18 mo 
of age (Table 4). It would be expected, therefore, that 18-mo-old females would have lower 
24-hydroxylase activity in intestine compared with all other groups studied. Some other 
regulator must be at work in this instance. 
Plasma PTH concentration increased with age in both male and female rats (Table 
3). This may be a response to, or cause of, the down-regulation of PTH receptors reported 
in old rats (51,52). Age-related increases in plasma PTH concentrations must be caused by 
increased secretion, because clearance of PTH is not changed by aging (54). The decline in 
intestinal Ca absorption with age also could result in increased PTH secretion, because low 
plasma Ca concentration stimulates PTH secretion (62). In this study, however, plasma Ca 
concentrations did not change with age. An alternative explanation for increased plasma 
PTH concentrations in older animals is that the "set point" of plasma Ca concentration for 
PTH release increases with aging (56, 57). That is, PTH can be secreted at higher plasma 
Ca concentrations, which usually suppress PTH secretion (56, 57, 58). 
Plasma l,25(OH)2D3 concentration declined (P <0.05) with age for both male and 
female rats (Table 4). The activity of la-hydroxylase, which converts 25(OH)D3 to the 
biologically active l,25(OH)2D3 in the kidney (12, 13), decreases with aging (59, 60). In 
male rats from 6- to 18-mo-old, Wada et a/ (61) found that both metabolic clearance rate and 
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production rate of l,25(OH)2D3 increased with age, resulting in no change in plasma 
I,25(0H)2D3 concentrations after 6 mo of age. An increase in metabolic clearance rate 
would support our findings of increased activity of renal 24-hydroxylase with aging. 
Metabolic clearance rate is determined by catabolism rates in all tissues. Although we found 
decreased 24-hydroxylase activity in intestine of older rats, the activity rates in kidney are 
much greater, making renal l,25(OH)2D3 catabolism more important in determining 
metabolic clearance rate. Production rate reflects synthesis rates. The age-related decrease 
in concentration of plasma l,25(OH)2D3 that we found is a reflection of both synthesis and 
degradation rates, and, in this case, catabolism rate must be greater than synthesis rate. This 
decrease took place over a wider age range than that studied by Wada et al (61). We also 
saw no significant decrease in plasma l,25(OH)2D3 concentrations of rats between 6 and 18 
mo of age. Although PTH stimulates la-hydroxylase activity in kidney (12,13), the 
down-regulation of PTH receptors seen in aging could explain the lower plasma 
1,25(0H)2D3 concentrations in older animals, despite the greater plasma PTH 
concentrations. In combination with an age-related decrease in l,25(OH)2D3 synthesis, the 
increased activity of renal 24-hydroxylase in old rats (Table 1) would contribute to the 
observed decline in plasma l,25(OH)2D3 concentrations with aging. Other factors 
influencing age-related declines in plasma l,25(OH)2D3 concentration include non-
absorption of dietary precursors or a decline in synthesis of precursors in skin. 
At 2.5 mo of age, females had lower (P <0.05) abundance of CaBP-9K and CaBP-
9K mRNA in intestinal mucosa than did the males (Fig. 5). Because the expression of 
CaBP-9K is absolutely dependent on l,25(OH)2D3 (21, 22), this gender difference is likely 
to be the result of lower (P <0.05) plasma l,25(OH)2D3 concentrations in females 
compared with males at this age (Table 4). Additionally, amounts of kidney CaBP-28K and 
CaBP-28K mRNA, whose expression also is stimulated by l,25(OH)2D3, were lower (P 
<0.05) in females than in males at 2.5 mo of age (Fig. 2). Gender differences in expression 
of genes regulated by l,25(OH)2D3 during ages at which bones are developing may be 
important in determining peak bone density and development of osteoporosis later in life. 
Kidney 24-hydroxylase activity (Table 1) and 24-hydroxylase mRNA abundance 
(Fig. 3) was lower (P <0.05) in females than in males at 2.5 mo of age, but only kidney 24-
hydroxylase mRNA abundance (Fig. 6) was lower ( P< 0.05) in females than in males at 18 
mo of age. At 2.5 mo of age, PTH suppression of kidney 24-hydroxylase expression 
seems to override stimulation by l,25(OH)2D3, resulting in males having greater 24-
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hydroxylase activity than do females. At 18 mo of age, PTH effects on kidney 24-
hydroxylase are blunted because of down-regulation of PTH receptors (51, 52). At this 
age, plasma l,25(OH)2D3 concentrations may be more influential in regulation of 24-
hydroxylase expression. 
Intestinal 24-hydroxylase mRNA and l,25(OH)2D3-stimulated 24-hydroxylase 
activity was greater (P <0.05) in males than in females at 2.5 mo of age (Table 2 and Fig. 
6). Parathyroid hormone does not regulate 24-hydroxylase mRNA expression in intestine, 
as it does in kidney (14). Differences between males and females in intestinal 24-
hydroxylase activity (Table 2) at 2.5 mo of age, therefore, can be explained by differences 
in plasma l,25(OH)2D3 concentrations between genders (Table 4). 
Plasma l,25(OH)2D3 concentrations were similar or lower (P <0.05) in females 
than in males at all ages (Table 4). At younger ages, this may in part be a result of greater 
plasma PTH concentrations in males than in females, because PTH stimulates la-
hydroxylase synthesis of l,25(OH)2D3 in kidney (12, 13). The down-regulation of PTH 
receptors, which occurs with aging (51,52), could eliminate PTH differences as an 
explanation for differences in plasma l,25(OH)2D3 concentrations between older males and 
females. The 24-hydroxylase enzyme regulates l,25(OH)2D3 concentrations by 
catabolizing the hormone (60). In 2.5-mo-old rats, however, 24-hydroxylase activity in 
kidney (Table 1) and l,25(OH)2D3-stimulated 24-hydroxylase activity in intestine (Table 2) 
both were lower (P <0.05) in females than in males. If this catabolic activity were the major 
determinant of plasma 1,25(OH)2D3 concentrations at this age, females should have more 
plasma l,25(OH)2D3 compared with males. In fact, the opposite is true. Synthesis rates, 
therefore, must be more important than catabolism rates in determining plasma 
1,25(0H)2D3 concentrations at 2.5 mo of age. In contrast to results in 2.5-mo-old rats, at 
18 mo of age, both renal 24-hydroxylase activity (Table 1) and l,25(OH)2D3-stimulated 
intestinal 24-hydroxylase activity were greater (P <0.05) in females than in males. At this 
age, when PTH effects on 1 «-hydroxylase activity are blunted by down-regulation of renal 
PTH receptors (51, 52), it would make sense that 24-hydroxylase catabolism would be the 
major determinant of plasma 1,25(0H)2D3 concentrations. 
Plasma PTH concentration was less (P <0.05) in females than in males at 2.5 mo of 
age (Table 3). This gender difference may contribute to the lower plasma concentrations of 
1,25(0H)2D3 in females compared with males at this age (Table 4), because PTH stimulates 
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the la-hydroxylase enzyme to synthesize l,25(OH)2D3, and suppresses 24-hydroxylase 
catabolism of l,25(OH)2D3 in the kidney (12, 13). 
The original observation that kidney 24-hydroxylase activity (Table 1) and 24-
hydroxylase mRNA abundance (Fig. 3) are greatly increased in old rats suggests that 
increased renal metabolism of l,25(OH)2D3 may contribute to the age-related decline in 
plasma l,25(OH)2D3 concentrations observed in older animals. This in turn may contribute 
to age-related bone loss. 
Male and female rats were similar over the age span studied for many of the factors 
examined. Most gender differences were found at sexual maturity (2.5-mo-old). The 
differences between males and females at this age may be a result of lower plasma 
1,25(0H)2D3 concentrations in females compared with males. The combined effects of 
these gender differences at ages when peak bone density is being developed may contibute 
to the greater incidence of osteoporosis in females compared with males. 
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PAPER IL EFFECTS OF AGE AND DIETARY CALCIUM 
DEPLETION ON GENES REGULATED BY 
1,25-DIHYDROXY VITAMIN D3 
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ABSTRACT 
Age-related changes in the factors that regulate Ca homeostasis may affect how older 
animals respond to stresses such as dietary Ca deficiency. Young (3-wk-oId) and old (18-
mo-old) male Fischer 344 rats were fed diets containing either 1% or 0.02% Ca for 4 wk. 
In young rats, renal 1,25-dihydroxyvitamin D3 [l,25(OH)2D3] receptors (VDR) and VDR 
mRNA content significantly declined as dietary calcium (Ca) declined, as has been 
previously shown by Goff et al. (1). In contrast, renal VDR in old rats was not affected by 
dietary Ca deficiency. Expression of the renal vitamin Dg-dependent calcium binding 
protein (CaBP-28K) mRNA also decreased in response to dietary Ca deficiency in young, 
but not in old, rats. Dietary Ca deficiency caused a decrease in kidney la,25-
dihydroxyvitamin D-24-hydroxylase (24-hydroxylase) mRNA abundance in 1-mo-old rats 
but resulted in a slight increase or no change in kidney 24-hydroxylase mRNA from the 
already elevated amounts in 18-mo-old rats. Intestinal CaBP-9K mRNA abundance 
increased in response to Ca deficiency only in young rats. Dietary Ca deficiency caused an 
increase in intestinal 24-hydroxylase mRNA content in 1-mo-old males, but either a slight 
decrease or no change was seen in 18-mo-old males. Plasma l,25(OH)2D3 concentrations 
increased in response to dietary Ca deficiency in young rats. In old rats, however, plasma 
1,25(0H)2D3 concentrations were lower and increased much less in response to dietary Ca 
changes. Increased renal catabolism of 1,25(0H)2D3 may be responsible for low plasma 
1,25(0H)2D3 concentrations observed in the older animal. These results indicate that the 
ability of old rats to adapt to dietary Ca deficiency is severely impaired. The reason for this 
inability to adapt seems to be because they are unable to respond to Ca deficiency by 
increasing renal production of 1,25(0H)2D3. Without this response, the old rats are unable 




Plasma and extracellular fluid calcium (Ca) concentrations are maintained within a 
relatively narrow range (2, 3). When deviations from this range occur, such as when 
inadequate amounts of Ca are available through absorption from the diet, the parathyroid 
hormone (PTH)-vitamin D endocrine system acts to maintain plasma Ca concentrations 
through multiple mechanisms (2, 3). These mechanisms include increasing tlie efficiency of 
Ca absorption in the intestine (2,4, 5) and increasing Ca mobilization from bone (6,7, 8). 
Aging animals often exhibit changes in factors that are part of the PTH-vitamin D 
endocrine system. Efficiency of absorption of Ca from the diet is poor (9, 10), plasma 
1,25-dihydroxyvitamin D3 [l,25(OH)2D3] concentrations have been found to both decrease 
(11,12) and remain unchanged (13, 14), and plasma PTH concentrations tend to be 
elevated chronically (15,16). These age-related changes in factors that maintain plasma Ca 
homeostasis may result in inappropriate responses to perturbations of Ca balance. If Ca 
homeostasis is not adequately maintained, diseases such as osteoporosis can develop. 
Both formation and catabolism rates determine the circulating concentrations of 
1,25(0H)2D3. In a feedback mechanism, l,25(OH)2D3 induces its own catabolism by 
stimulating the 1 a,25-dihydroxyvitamin D-24-hydroxylase enzyme (24-hydroxylase) in 
target tissues of kidney and intestine (17,18). High plasma l,25(OH)2D3 concentrations 
also inhibit the activity of the 25-hydroxyvitamin D-la-hydroxylase enzyme (la-
hydroxylase), which synthesizes l,25(OH)2D3 from 25(OH)D3 (19,20,21). In the 
kidney, PTH induces the activity of la-hydroxylase and suppresses 24-hydroxylase (22, 
23,24). PTH does not regulate 24-hydroxylase in the intestine (24). Age-related decreases 
in plasma l,25(OH)2D3 concentrations are partly a result of decreased renal la-hydroxylase 
activity (25, 26, 27). How aging affects renal 24-hydroxylase activity has remained 
controversial. Armbrecht et <3/ (13) showed that renal production of 24,25(OH)2D3 is 
increased in 13- and 25-mo-old compared with 3-mo-old male rats. Wada et al (14) have 
shown that both the production rate and metabolic clearance rate of l,25(OH)2D3 increase 
between 6 and 18 mo of age, resulting in no net change in plasma l,25(OH)2D3 
concentrations. These data suggest that 24-hydroxylase activity is increased with aging. 
More recently, however, Armbrecht and Boltz (28) showed that the expression of 24-
hydroxylase mRNA in kidney was lower in vitamin D deficient 12-mo-old compared with 
2-mo-old rats throughout a 48-h period after a dose of l,25(OH)2D3. 
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Evidence suggests that PTH regulates renal VDR and 24-hydroxylase, likely at the 
level of gene expression (1,24, 29). Goff et al{\) showed that when plasma l,25(OH)2D3 
concentrations are increased endogenously, by dietary Ca deficiency, renal VDR content 
decreased, despite equal or greater plasma l,25(OH)2D3 concentrations in the Ca deficient 
rats (1). Dietary Ca deficiency stimulates PTH secretion (6, 30), resulting in the increased 
plasma l,25(OH)2D3 concentrations (31). Reinhardt and Horst (29) showed that PTH 
down-regulates VDR and VDR mRNA in vitro, and also blocks up-regulation of VDR by 
1,25(0H)2D3 in vivo (29). Shinki etal (24) found that PTH inhibits 24-hydroxylase 
mRNA expression stimulated by l,25(OH)2D3 in rat kidney. Increased plasma PTH 
concentrations as a result of Ca depletion seem to act in opposition to l,25(OH)2D3 in 
regulation of gene expression (1,24, 29). Kidneys of old rats are less responsive to PTH, 
because PTH receptors are down-regulated with aging (32, 33). This down-regulation 
probably is a result of chronically elevated plasma PTH concentrations in old rats (32). 
In light of the many age-related changes in factors that are part of the PTH-vitamin D 
endocrine system, the purpose of this study was to determine whether these factors respond 
differently to the stress of dietary Ca deficiency in young (weanling) and old (senescent) 
rats. Specifically, we examined gene products regulated by l,25(OH)2D3, including the 
VDR, CaBP-28K, CaBP-9K, and the 24-hydroxylase enzyme. 
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MATERIALS AND METHODS 
Materials 
Crystalline l,25(OH)2D3 was a gift from Milan Uskokovic (Hoffmann-LaRoche, 
Inc., Nutley, NJ). Complementary DNA (cDNA) for rat VDR was provided by Wesley 
Pike (Ligand Pharmaceuticals, San Diego, CA). Mouse CaBP-28K cDNA was a gift from 
Sylvia Christakos (University of Medicine and Dentistry of New Jersey, Newark, NJ). M. 
Elizabeth Bruns (University of Virginia Medical School, Charlottesville, VA) provided the 
cDNA for mouse CaBP-9K. Kyuichiro Okuda (Hiroshima University School of Dentistry, 
Hiroshima, Japan) provided the cDNA for rat 24-hydroxylase. The a-[32p]-dCTP (3,000 
Ci/mmol, 10 mCi/ml) was purchased from Amersham Corp. (Arlington Heights, IL). 
01igo-d(T)i8 was from Pharmacia (Piscataway, NJ). All other chemicals were of analytical 
grade or higher. 
Animals 
Six male Fischer 344 rats were used for each experimental group. Weanling (3-wk-
old) rats were purchased from Harlan-Sprague-Dawley (Madison, WI), and 18-mo-old rats 
were purchased from the NIH (Bethesda, MD) aging colony. All rats were fed purified 
diets (Teklad, Madison, WI) containing either 1% or 0.02% Ca for 4 wk. Rats then were 
anesthetized with C02:02 (1:1) and decapitated. Blood was collected for analysis of plasma 
1,25(0H)2D3 concentrations. Mucosa was scraped from die proximal 20 cm of small 
intestine and divided in half. One-half was frozen in liquid N2 for later RNA extraction, and 
one-half was used to assay for VDR content. One kidney was removed and frozen in liquid 
N2 for RNA extraction, and the other kidney was assayed for VDR concentration. 
VDR Assay 
Kidneys or intestinal mucosa were minced and washed in ice cold Tris/NaCl buffer 
(10 mM Tris, pH 7.4, 50 mM NaCl) with 50 KlU/ml proteinase inhibitor (Trasylol, Mobay 
Chemical Corp., New York, NY). Tissue then was homogenized (20% w/v) in 500 mM 
KTD (500 mM KCl, 10 mM Tris, pH 7.4, 5 mM dithiothreitiol, 200 |ig/ml soybean trypsin 
inhibitor) (34) and centrifuged at 230,000 X g. Aliquots (50 |il) of the resulting supernatant 
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(cytosol) were incubated with 8 mM [3h]-1,25(OH)2D3 + 100-fold excess of l,25(OH)2D3 
in triplicate at 4 C for 16 h to estimate VDR binding sites. Bound and free hormone were 
separated by using hydroxyapatite. All VDR assays were corrected for non-specific 
binding. Cytosol protein concentration was determined by the Bradford method, with a 
bovine serum albumin (BSA) standard (35). 
Northern and Slot Blot Analyses 
RNA was isolated from kidney and intestinal mucosa by using an acid guanidinium 
thiocyanate-phenol-chloroform extraction (36). 01igo-d(T)-cellulose chromatography then 
was used to prepare poly(A)+ RNA. Poly(A)+ RNA (10-20 ng) was separated on a 1.2% 
formaldehyde-agarose gel and transferred to a Magna NT nylon membrane (Micron 
Separations Inc., Westboro, MA). For slot blot analysis, poly(A)+ RNA (1.25-5 |ig) was 
blotted onto Magna NT membranes by using a Minifold II slot blot apparatus (Schleicher 
and Schuell, Keene, NH). Poly (A)+ RNA was cross-linked to membranes by irradiation 
(UV Stratalinker, Stratagene Cloning Systems, La Jolla, CA). Restriction enzyme digestion 
was used to obtain a 1.7 kb rat VDR cDNA insert from the EcoRI site of pIBI76 (37), a 3.2 
Kb rat 24-hydroxylase cDNA insert from the EcoRI site of pUC19 (38), a 1.2 kb mouse 
CaBP-28K cDNA insert from the EcoRI site of pIBI76 (39), and a 0.2 kb mouse CaBP-9K 
cDNA insert from the EcoRI site of Bluescribe (40). A random primer oligolabeling kit 
(Pharmacia) was used to label the cDNA to a specific activity of lO^-lO^ dpm/|ig of DNA. 
Membranes were prehybridized for 1-2 h at 42 C in 5X SSPE (SSPE = 0.18 M NaCl, 10 
mM NaPO^, 1 mM EDTA pH 7.4), 50% formamide, 5X Denhardt's reagent [IX 
Denhardt's = 0.02% Ficoll (type 400), 0.02% polyvinylpyrrolidone, 0.02% BSA (fraction 
V)], 0.5% sodium dodecyl sulfate (SDS), and 100 |J.g/ml denatured herring sperm DNA. 
Hybridization was carried out overnight at 42 C in fresh prehybridization buffer plus 250 |J.g 
of transfer RNA (as a carrier) and 1-5 X 10^ cpm/ml of ^^P-labeled cDNA probe. 
Membranes were washed twice for 10 min at room temperature in 2X SSPE/0.1% SDS and 
then twice for 10 min at room temperature in O.IX SSPE/0.1% SDS. Imaging and 
quantitation of bands was done using an AMBIS Radioanalytic Imaging System (AMBIS, 
Inc., San Diego, CA). Autoradiography was carried out at -70 C for 12-168 h with 
XOMAT X-ray film (Eastman Kodak Co., Rochester, NY) with an intensifying screen. To 
normalize for the amount of poly(A)+ RNA loaded onto gels, membranes were hybridized 
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with a pd(T)i8 probe (41). The pd(T)ig was labeled with a-[32p]-dCTP by using a DNA 
3'-end-labeling system from Promega (Madison, WI). Membranes were prehybridized for 
10 min at room temperature in 5X SSPE and then hybridized for 1-2 h at room temperature 
in 5X SSPE, 5X Denhardt's reagent plus 200 pmol of [32p]-labeled pd(T)ig per 11 x 14 cm 
membrane. Washing was twice at room temperature in 2X SSPE/0.1% SDS. Imaging, 
quantitation, and autoradiography were performed as described for cDNA probes. 
Other Analyses 
A protein binding assay was used to measure l,25(OH)2D3 concentrations in plasma 
extracts and then corrected for nonspecific binding (42). Statistical differences were 
determined by using an Analysis of Variance test. Values were considered to be 
significantly different when P <0.05. 
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RESULTS 
We studied the expression of genes regulated by l,25(OH)2D3 in kidneys of one-
and 18-mo-old male rats fed either a normal Ca control diet or a Ca deficient diet. Kidney 
VDR concentration was not changed by age in rats fed a normal Ca diet. When rats were 
fed a Ca deficient diet, however, kidney VDR concentration decreased (P <0.05) in young 
(1 mo), but not old (18 mo), rats (Fig. 1). The mRNA for VDR in kidney responded in the 
same way to Ca deficiency as did the VDR protein (Fig. 2). 
Similarly to VDR and VDR mRNA in kidney, the amount of CaBP-28K mRNA in 
kidney decreased (P <0.05) in young, but not old, rats fed a Ca deficient diet (Fig. 3). 
Differently from VDR and VDR mRNA, however, renal CaBP-28K mRNA content was 
decreased (P <0.05) in old rats compared with young rats (Fig. 3). 
As seen in Figure 4, 24-hydroxylase mRNA abundance in kidney was increased 
markedly (P <0.05) in old rats compared with young rats. In response to dietary Ca 
depletion, 24-hydroxylase mRNA content in kidneys of young rats declined (P <0.05) (Fig. 
4). Kidney 24-hydroxylase mRNA content remained unchanged by Ca deficiency from the 
already elevated (P <0.05) amounts in old rats (Fig. 4). 
The effect of Ca deficiency on the expression of l,25(OH)2D3-regulated genes also 
was examined in intestine of one- and 18-mo-old male rats. As seen in Figure 5, intestinal 
VDR concentration was unchanged by age or by dietary Ca deficiency. Intestinal VDR 
mRNA also did not change with age or dietary Ca depletion (Fig. 6). 
In contrast, intestinal CaBP-9K mRNA content increased significantly (P <0.05) in 
response to dietary Ca deficiency in young rats (Fig. 7). In old rats, however, dietary Ca 
deficiency did not affect the abundance of intestinal CaBP-9K mRNA (Fig. 7). Intestinal 
CaBP-9K mRNA content decreased slightly, but not significantly, with age (Fig. 7). 
Similarly to intestinal CaBP-9K mRNA, the amount of message for 24-hydroxylase 
in intestine decreased (P <0.05) with age (Fig. 8). Also, in response to dietary Ca 
depletion, intestinal 24-hydroxylase mRNA content increased significantiy (P <0.05) in 
young rats (Fig. 8). This increase in intestinal 24-hydroxylase mRNA abundance in 
response to depletion of dietary Ca was not seen in old rats (Fig. 8). 
Dietary Ca deficiency resulted in a significant increase (P <0.05) in plasma 
1,25(0H)2D3 concentrations in young rats (Fig. 9). Plasma l,25(OH)2D3 concentrations 
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1 Month 18 Months 
FIGURE 1. Effect of age and Ca deficiency on kidney VDR. Values are the mean + 
SEM for six rats. * Indicates means significantly (P <0.05) different 
between rats of the same age fed different diets. ° Indicates means 
significantly (P <0.05) different between 1- and 18-mo-old rats fed the 
same diet. 
FIGURE 2. Effect of dietary Ca deficiency on kidney VDR mRNA expression. VDR 
mRNA values are from slot blots and are presented as a fraction of the value 
for 1-mo-old rats fed the 1% Ca diet after correction for background and 
normalization to pd(T)]g. Quantitation was done by using an AMBIS 
Radioanalytic Imaging System (AMBIS, Inc., San Diego, CA). * Indicates 
means significantly (P <0.05) different between rats of the same age fed 
different diets. ° Indicates means significantly (P <0.05) different between 
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FIGURE 3. Effect of dietary Ca deficiency on kidney CaBP-28K mRNA expression. 
CaBP-28K mRNA values are from slot blots and are presented as a fraction 
of the value for 1-mo-old rats fed the 1 % Ca diet after correction for 
background and normalization to pd(T)ig. Quantitation was done by using 
an AMBIS Radioanalytic Imaging System (AMBIS, Inc., San Diego, CA). 
* Indicates means significantly (P <0.05) different between rats of the same 
age fed different diets. ° Indicates means significantly (P <0.05) different 
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FIGURE 4. Effect of age and Ca deficiency on kidney 24-hydroxylase mRNA. 24-
Hydroxylase mRNA values are from slot blots and are presented as a 
fraction of the value for 1-mo-old rats fed the 1% Ca diet after correction for 
background and normalization to pd(T)ig. Quantitation was done by using 
an AMBIS Radioanalytic Imaging System (AMBIS, Inc., San Diego, CA). 
° Indicates means significantly (P <0.05) different between 1- and 18-mo-
old rats fed the same diet. ^ Indicates means significantly (P <0.05) different 
between rats of the same age fed different diets. 
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FIGURE 5. Effect of age and Ca deficiency on intestinal VDR. Values are the mean + 
SEM for six rats. 
FIGURE 6. Effect of dietary Ca deficiency on intestinal VDR niRNA expression. VDR 
mRNA values are from slot blots and are presented as a fraction of the value 
for 1-mo-old rats fed the 1% Ca diet after correction for background and 
normalization to pd(T)ig. Quantitation was done by using an AMBIS 
Radioanalytic Imaging System (AMBIS, Inc., San Diego, CA). * Indicates 
means significantly (P <0.05) different between rats of the same age fed 
different diets. ° Indicates means significantly (P <0.05) different between 
1- and 18-mo-old rats fed the same diet. 
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FIGURE 7. Effect of dietary Ca deficiency on intestinal CaBP-9K mRNA expression. 
CaBP-9K mRNA values are from slot blots and are presented as a fraction of 
the value for 1-mo-old rats fed the 1% Ca diet after correction for 
background and normalization to pd(T)]g. Quantitation was done by using 
an AMBIS Radioanalytic Imaging System (AMBIS, Inc., San Diego, CA). 
* Indicates means significantly (P <0.05) different between rats of the same 
age fed different diets. ° Indicates means significantly (P <0.05) different 
between 1- and 18-mo-old rats fed the same diet. 
Intestine CaBP-9K mRNA 
Fraction of 1-Month /1% Ca 
s g 
FIGURE 8. Effect of age and Ca deficiency on intestinal 24-hydroxylase mRNA. 24-
Hydroxylase mRNA values are from slot blots and are presented as a 
fraction of the value for 1 -mo-old rats fed the 1 % Ca diet after correction for 
background and normalization to pd(T)ig. Quantitation was done by using 
an AMBIS Radioanalytic Imaging System (AMBIS, Inc., San Diego, CA). 
0 Indicates means significantly (P <0.05) different between 1- and 18-mo-
old rats fed the same diet. ^ Indicates means significantly (P <0.05) different 
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FIGURE 9. Effect of dietary Ca deficiency on plasma l,25(OH)2D3 concentration. 
Values are means ± SEM for six rats. * Indicates means significantly 
(P <0.05) different between rats of the same age fed different diets. 
0 Indicates means significantly (P <0.05) different between 1- and 18-mo-
old rats fed the same diet. 
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were not changed by Ca deficiency, however, in old rats (Fig. 9). In this experiment, 
plasma l,25(OH)2D3 concentrations were not affected by aging (Fig. 9). 
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DISCUSSION 
Changes often occur with aging in factors that are part of the PTH-vitamin D 
endocrine system (9, 10, 11, 12, 15). Because this system maintains homeostasis of 
plasma and extracellular fluid Ca (2, 3), changes in these factors may result in inappropriate 
responses to perturbations of Ca balance. Inadequate maintenance of Ca homeostasis can 
lead to increased incidence of diseases such as osteoporosis. Because of these age-related 
changes in regulation of Ca balance, this study compared adaptive responses of young (1-
mo-old) and old (18-mo-oId) male rats to dietary Ca deprivation. Specifically, we examined 
the expression of l,25(OH)2D3-regulated genes whose products are involved in regulation 
of Ca homeostasis. 
Dietary Ca deficiency caused a tremendous increase in plasma l,25(OH)2D3 
concentrations in young, but not in old, rats (Fig. 9). This response influenced genes 
stimulated by l,25(OH)2D3 in the intestine. Expression of both CaBP-9K mRNA (Fig. 7) 
and 24-hydroxylase mRNA (Fig. 8) was increased in intestine of young, but not old rats in 
response to Ca depletion. Intestinal VDR and VDR mRNA contents, however, were not 
changed by Ca deficiency in rats of either age (Figs. 5 and 6). Goff et al (I) found similar 
results for intestinal VDR concentrations in young rats fed a Ca deficient diet. Increased 24-
hydroxylase activity, as a result of increased expression 24-hydroxylase mRNA, could 
cause a decrease in the tissue concentrations of l,25(OH)2D3 in intestine (18,43), 
effectively preventing up-regulation of VDR by l,25(OH)2D3 in intestine. 
The 1,25(0H)2D3 hormone acts to stimulate rat intestinal CaBP-9K gene expression 
by both rapid stimulation of transcription and post-transcriptional stabilization of the CaBP-
9K transcript (44). These different actions of 1,25(0H)2D3 may explain the differences in 
expression of VDR and CaBP-9K in intestine in response to Ca depletion. Huang et al (45) 
found that, in vitamin D deficient adult rats, increased expression of intestinal CaBP-9K 
mRNA in response to exogenous l,25(OH)2D3 treatment was not accompanied by a 
corresponding increase in VDR synthesis. 
Increased intestinal 24-hydroxylase mRNA content during Ca deficiency likely leads 
to greater 24-hydroxylase activity as part of a mechanism by which l,25(OH)2D3 regulates 
its own plasma concentrations (19, 46). Additionally, in a state of Ca depletion, when 
plasma PTH concentrations are elevated, 24-hydroxylase activity in kidney is suppressed 
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(22,47). Therefore, the intestine would become more important as a catabolic site for 
excess l,25(OH)2D3 during Ca deficiency. 
In contrast to what happened in the intestine, the expression of genes regulated by 
l,25(OH)2D3 in kidney was decreased in young rats in response to Ca deficiency (Figs. 1-
4). These decreases did not occur in kidneys of old rats (Figs. 1-4). Others have found that 
Ca deficiency results in decreased activity of renal 24-hydroxylase in young rats (13,43, 
48,49) but not in old rats (13). These findings correlate with our results for the 24-
hydroxylase message. The difference between intestine and kidney in response to Ca 
depletion can be explained in part by the role of PTH. In the kidney, PTH suppresses 
l,25(OH)2D3-stimulated expression of 24-hydroxylase, but PTH has no effect on 
l,25(OH)2D3-stimulated expression of 24-hydroxylase in intestine (24). The PTH also 
negatively regulates VDR expression (29). Along with the fact that PTH receptors have 
been found in kidney, but not in intestine, these results suggest that PTH has no direct 
effects on intestine. 
It is not known whether PTH directly affects CaBP-28K gene expression in kidney. 
Expression of renal CaBP-28K is dependent on l,25(OH)2D3 (2), however, and VDR 
mediate l,25(OH)2D3-stimulated gene expression (7, 50). Therefore, PTH could indirectly 
down-regulate renal CaBP-28K expression through suppression of the VDR gene, despite 
high plasma l,25(OH)2D3 concentrations. In contrast to our results, Huang and Christakos 
(51) showed that abundance of rat renal CaBP-28K and CaBP-28K mRNA was unchanged 
by low dietary Ca, although plasma l,25(OH)2D3 concentrations were markedly elevated. 
Additionally, Bogden et al (52) showed increased renal CaBP-28K concentrations in 
weanling rats fed a 0.1% Ca diet compared with those fed a 2.5% Ca diet for one yr. 
Renal PTH receptors are down-regulated in old rats (32), causing a blunting of 
response to changes in PTH concentrations (33). Armbrecht etal (53) showed that the 
degree of stimulation of cAMP production by PTH was decreased by 25% in 12-mo-old 
male rats compared with 1-mo-old rats. This down-regulation of PTH receptors in old rats 
can explain the lack of change in kidney content of VDR, VDR mRNA, 24-hydroxylase 
mRNA, and CaBP-28K mRNA, as well as the lack of increase in plasma l,25(OH)2D3 
concentrations in old rats fed a Ca deficient diet. 
Abundance of CaBP-28K mRNA was lower in old rats than in young rats (Fig. 3), 
despite unchanged plasma l,25(OH)2D3 concentrations (Fig. 9), kidney VDR content (Fig. 
1), and kidney VDR mRNA abundance (Fig. 2). Koszewski et al (54) also found that renal 
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VDR concentration did not change with aging in male rats. Additionally, however, 
Koszewski et al (54) found that VDR from kidneys of old rats had decreased affinity for 
binding to DNA-cellulose compared with VDR from kidneys of young rats. This decrease 
in expression of renal CaBP-28K mRNA may be a result of decreased binding of VDR to 
the DNA (54). 
Abundance of 24-hydroxylase mRNA in kidneys (Fig. 4) increased with aging. An 
increase in renal 24-hydroxylase activity also occurs with aging (see Paper I). These results 
correspond with observed increases in renal 24,25(OH)2D3 production (13, 53) and 
metabolic clearance rate of l,25(OH)2D3 (14) with aging. In contrast, Armbrecht and Boltz 
(28) found that the expression of 24-hydroxylase mRNA in kidney was lower in old rats 
throughout a 48-h period after a dose of l,25(OH)2D3. The rats in this experiment (28), 
however, were first made vitamin D deficient by feeding a low Ca, 0.8% strontium diet for 
6 d. Any other physiological effects of this treatment are unknown; so, this data cannot be 
used to explain what is happening during aging of normal animals. Down-regulation of 
PTH receptors seen in old rats (16, 32, 33) would result in an increase in 24-hydroxylase 
activity by way of decreasing suppression of the enzyme, and plasma l,25(OH)2D3 
concentrations were unchanged by aging in this experiment (Fig. 9). It seems then that the 
PTH effects must override the effects of l,25(OH)2D3. 
These results suggest that old rats are unable to adapt to dietary Ca deficiency. The 
reason for this inability to adapt seems to be because they are unable to respond to Ca 
deficiency by increasing renal production of l,25(OH)2D3. Without an adaptive response to 
Ca deficiency, old rats are unable to appropriately regulate genes whose products are 
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The most notable finding from the first paper was that females had less intestinal 
CaBP-9K and CaBP-9K mRNA than did males at sexual maturity (2.5-mo-oId), when a 
large part of bone development takes place. Females also had lower plasma l,25(OH)2D3 
concentrations compared with males at this age. Females may have decreased la-
hydroxylase activity compared with males. Concentrations of plasma PTH, which 
stimulates la-hydroxylase activity, also were greater in males than in females at 2.5 mo of 
age. Both kidney and intestinal 24-hydroxylase activities were lower in females than in 
males at 2.5 mo of age. Lower plasma l,25(OH)2D3 levels in females, therefore, are not a 
result of increased catabolism of l,25(OH)2D3. Because females have less CaBP-9K and 
CaBP-9K mRNA intestine tiian do males in at developing ages, they are likely to have 
poorer absorption of dietary Ca and may not adapt as well as do males to Ca deprivation. 
This could contribute to failure of females to attain as great of peak bone mass as do males. 
This study of males and females suggests that it is important to look at factors which may 
contribute to involutional osteoporosis during bone development, before age-related bone 
loss begins, and not just after the disease has taken over. 
An important observation from these studies is that expression of the "constitutively" 
expressed P-actin message changes with aging. This also is true for another "constitutive" 
protein, cyclophilin. This is a very important fact to know when choosing controls for 
aging studies, because if the control also is changing, results will be altered. These 
observations offer a good example of why not to just assume that the way "everyone else" 
does it is necessarily the right way. 
These studies confirm at the message level that old rats adapt less well than do 
young rats to dietary Ca restriction and seem to have a blunted responsiveness to PTH. 
This lack of adaptation to dietary Ca depletion is at least in part a result of decreased 
expression of intestinal CaBP-9K, which important for absorption of dietary Ca, in older 
animals. 
The increased catabolism of l,25(OH)2D3 in kidney via 24-hydroxylase found in 
old rats is a unique new observation. This increased catabolism would add to the already 
decreased l,25(OH)2D3 synthesis rates found in older animals to further decrease plasma 
1,25(0H)2D3 concentrations in older animals. Because 24-hydroxylase activity declined 
with age in intestine, the mechanisms of enzyme control must be tissue-specific. An 
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interesting future project would be to determine the specific cause of increased renal 24-
hydroxylase activity in old animals. It could be a result of simply lack of suppression by 
PTH, or possibly increased sensitivity to l,25(OH)2D3. Perhaps other stimulatory or 
inhibitory factors are involved as well. 
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APPENDIX. AGE EFFECTS ON PROBES USED FOR NORMALIZATION 
OF NORTHERN BLOTS 
I l l  
AGE EFFECTS ON PROBES USED FOR 
NORMALIZATION OF NORTHERN BLOTS 
When these studies were begun, a P-actin cDNA probe was used to check for 
accuracy of spectrophotometric quantitation and loading of poly(A)+ RNA onto gels for 
Northern blots. In these beginning studies, RNA from intestine of young male rats was 
used. In order to determine what quantitiy of poly(A)+ RNA was needed to detect VDR 
mRNA, a Northern blot was run with 5, 10, 20, and 40 |j,g of poly(A)+ RNA from the 
intestine of a 1-mo-old male rat (Fig. Al). Considering results from probing the blot with 
p-actin and VDR cDNAs, quantitation and gel-loading seem to be accurate, and P-actin 
mRNA seems to be an appropriate control. 
When comparing VDR mRNA in intestine between 1-mo-old (young) and 18-mo-
old (old) male rats, we observed that VDR mRNA content declined with age in intestine, as 
does the concentration of VDR protein. The P-actin mRNA content also seemed to decline 
with age in intestine, however. To clarify what was happening, poly(A)+ RNA was very 
carefully re-quantitated, and a Northern blot was run with 20 |ig of poly(A)+ RNA from 
young, and 40 |ig of poly(A)+ RNA from old rat intestine (Fig. A2). Abundance of VDR 
and P-actin mRNAs appears to be approximately equal in the two lanes (Fig. A2). This 
result would imply that abundance of both messages decreases with age. Additionally, a 
cyclophilin cDNA probe was tried as an alternative control. The cyclophilin mRNA content 
also seemed to decrease with age in intestine (Fig. A2). 
The P-actin mRNA is commonly used for normalization of Northern blots, because 
P-actin mRNA is considered to be constitutively expressed, and so is not altered by most 
experimental treatments. Cyclophilin mRNA also is considered to be constitutively 
expressed. The observation that abundance of P-actin and cyclophilin mRNAs in rat 
intestine seem to decrease with age, however, would incorrectiy alter quantitative results 
from Northern blots of RNA from animals of different ages that were corrected for mRNA 
loading with either P-actin or cyclophilin mRNA. For example, if the intestinal VDR 
mRNA, which declines with age, were normalized for P-actin mRNA content, it would 
seem quantitatively that no change occurred in intestinal VDR mRNA with aging. This is 
the result we observed. 
We also considered the possibility that the degree of enrichment of poly(A)+ RNA 
prepared by oligo-d(T)-cellulose chromatography was different for RNA from young and 
FIGURE Al. Northern blot of 5, 10,20, and 40 |ig of intestinal poly(A)+ RNA from a 1-mo-
old maie rat. The blot was probed with both VDR cDNA and p-actin cDNA to 
test the accuracy of loading poly(A)+ RNA on gels. 
Poly (A) + RNA 
5 |Llg 10 ng 20 ^g 40 ^ig 
4.5 Kb VDR 
R-Actin 
Intestine from l-mo-old Rat 
FIGURE A2. Northern blot of 20 |ig of intestinal poly(A)+ RNA from a 1-mo-old maie rat, and 
40 |J.g of intestinal poly(A)+ RNA from an 18-mo-old maie rat. The blot was 
probed with VDR cDNA, P-actin cDNA, and cyclophilin cDNA. 
Poly (A) + RNA 
Young Old 
20 40 Hg 
4.5 Kb VDR 
2.1 Kb 
B-Actin 
1.0 Kb Cyclophilin 
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old rats, or that old rats had less poly(A)+ RNA in than did young rats, because every 
mRNA that had been tested so far seemed to decline with age in intestine. For these 
reasons, we decided to try using a pd(T)ig probe to normalize for quantity of poly(A)+ 
RNA applied to membranes. Because the pd(T)ig binds to poly(A)+ tails on mRNA, the 
pd(T)i8 probe measures the total amount of poly(A)+ RNA on the blot instead of only the 
message from one gene. Use of the pd(T)]g probe also allows for correction for any 
differences in the degree of recovery of poly(A)+ RNA from each total RNA sample in the 
poly(A)+ RNA selection process. Unlike P-actin mRNA, poly(A)+ RNA, as detected by 
using a pd(T)ig probe, did not change with age in intestine or kidney of rats (Fig. A3). 
Therefore, we chose to use pd(T)ig as a control probe for aging studies. 
FIGURE A3. Effect of age on kidney and intestinal P-actin mRNA and poIy(A)+ RNA 
expression. Values for intestinal P-actin mRNA are the mean ± S EM for 6 rats. 
Values for kidney P-actin mRNA are the mean + S EM for 12 rats. Values for 
intestinal poly(A)+ RNA are the mean ± SEM for 24 rats. Values for kidney 
poly(A)+ RNA are the mean ± SEM for 27-28 rats. Values are from Northern 
and slot blots and are presented as a fraction of the lane on the blot with the 
greatest number of counts, after correction for background. Quantitation was 
done by using an AMBIS Radioanalytic Imaging System (AMBIS, Inc., San 
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